Dale J. Pullen

Dale J. Pullen

PROFESSOR EMERITUS

Department:
SOM-Pediatrics

Email:
jpullen@umc.edu

Biography

Dr. Pullen served as Director of the UMMC Division of Pediatric Hematology/Oncology and Director of the MS Children’s Cancer Clinic from 1969 through 2005. Since January 2006, she has worked part time at UMMC as Emeritus Professor, Department of Pediatrics, Division of Pediatric Hematology/Oncology.

Dr. Pullen’s primary research interest has been in the classification and treatment of childhood acute lymphocytic leukemia (ALL) through her work in the national Pediatric Oncology Group (POG), and the Children’s Oncology Group (COG).

Education

University of Tennessee Health Sciences Ctr, Memphis TN, MD, NIH Postdoctoral Traineeship in Pediatric Hematology/Oncology1969
University of Tennessee Health Sciences Ctr, Memphis TN, MS Degree obtained during fellowship training, Pediatrics1969
Charity Hospital of LA, Tulane University School of Medicine, New Orleans LA, Residency in Pediatrics1964
Parkland Memorial Hospital, Dallas TX, Internship (Rotating)1962
Tulane University School of Medicine, New Orleans LA, MD, Medicine1961
Millsaps College, Jackson MS, BS, Chemistry1957

Specialty Certification Licensure

Re-certification, American Board of Pediatrics, Subboard of Pediatric Hematology/Oncology06/1999 - Present
Certification, Certification (permanent), American Board of Pediatrics, Subboard of Pediatric Hematology/Oncology11/1974 - Present
Certification, Certification (permanent), American Board of Pediatrics10/1969 - Present
Licensure, Mississippi State Medical License1969 - Present
Licensure, Tennessee State Medical License1966 - Present
Licensure, Louisiana State Medical License1961 - Present

Current Positions

Professor Emeritus, School of Medicine, Department of Pediatrics2006 - Present
The University of Mississippi Medical Center
Jackson, Mississippi 39216

Academic Appointments or Other Previous Appointments

Billy S. Guyton (formerly F.A.P. Barnard) Distinguished Professor, University of Mississippi Medical Center, School of Medicine1993 - 12/1998
Professor, University of Mississippi Medical Center, School of Medicine, Department of Pediatrics06/1982 - 12/2005
Associate Professor, University of Mississippi Medical Center, School of Medicine, Department of Pediatrics06/1975 - 06/1982
Assistant Professor, University of Mississippi Medical Center, School of Medicine, Department of Pediatrics07/1969 - 06/1975

Sponsored Program Funding

Extramural, Children's Oncology Group Phase I/Pilot Consortium, National Cancer Institute08/2003 - 07/2006
Extramural, Pediatric Oncology Group ALinC 16/17 Classificiation, National Cancer Institute03/2003 - 04/2005
Extramural, Children's Oncology Group, National Cancer Institute01/2003 - 10/2005
Extramural, Children's Oncology Group Phase I/Pilot Consortium Per Case Reimbursement, National Cancer Institute01/2003 - 09/2005
Extramural, Children's Oncology Group Per Case Reimbursement, National Cancer Institute01/2002 - 09/2005
Extramural, Pediatric Oncology Group, National Cancer Institute09/1974 - 12/2003

Publications

Journal Article

Asselin BL, Devidas M, Chen L, Franci VL, Pullen J, Borowitz MJ, Hutchinson RE, Ravindranath Y, Armenian SH, Camitta MB, Lipshultz SE Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children's Oncology Group randomized trial Pediatric Oncology Group 9404 J of Clin Oncol 2016; 34(8):854-8622016
Sitthi-Amorn J, Herrington B, Megason G, Pullen J, Gordon C, Hogan S, Koganti T, Hicks C Transciptome analysis of minimal residual disease in subtypes of pediatric B Cell Acute Lymphoblastic Leukemia Clinical Medicine Insights: Oncology 2015; 951-9602015
Dreyer ZE, Hilden JM, Jones T, Devidas M, Winick NJ, Willman CL, Harvey RC, Chen I-M, Behn FG, Pullen J, Wood BL, Carroll AJ, Heerema NA, Felix CA, Robinson B, Reaman GH, Salzer WL, Hunger SP, Carroll WL, Camitta BM Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3) Pediatr Blood Cancer 2015; 62:419-4262015
Tower RL, Jones T, Camitta BM, Asselin B, Bell B, Chauvenet A, Defidas M, Halperin E, Pullen J, Shister J, Taylor S, Winich N, Kurtzberg J Dose intensification of methotrexate and cytarabine during intensivied continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: A randomized study conducted by the Pediatric Hematology/Oncology Group J Pediatr Hematol Oncol 2014; 36(5):353-3612014
Chen I, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H, Borowitz MJ, Camitta BM, Carroll AJ, Devidas M, Pullen DJ, Payne-Turner D, Tasian SK, Reshmi S, Cottrell CE, Reaman GH, Bowman WP, Carroll WL, Loh ML, Winick NH, Hunger SP, Willman CL Outcome modeling with CRLF2, IKZF1, JAK and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group study Blood, 2012; 119(15):3512-35222012
Bowman WP, Larsen E, Devidas M, Linda SB, Blach L, Carroll AJ, Carroll WL, Pullen J, Shuster J, Willman CL, Winich N, Camitta B, Hunger S, Borowitz M Influence of minimal residual disease (MRD) on outcomes in children with high risk acute lymphocytic leukemia: Results of Pediatric Oncology Group trial 9906 Pediartr Blood Cancer, 2011; 57(4):569-5772011
Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchinson R, Lipshultz SE, Camitta BM Effectiveness of high dose methotrexate in T-cell lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A randomized study by the Children's Oncology Group (POG 9404) Blood, 2011; 118(4), 874-8822011
Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL, Pullen J, Whitlock JA, Willman CL, Winick NJ, Camitta BM, Hunger SP: Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: A report from the Children's Oncology Group Blood, 2010; 116(7):1045-10502010
Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, Camitta BM: Long-term results of the Pediatric Oncology Group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the Children's Oncology Group Leukemia, 2010; 24:355-3702010
Rubnitz JE, Wichlam D, Devidas M, Shuster J, Linda SB, Kurtzberg J, Bell B, Hunger SP, Chauvenet A, Pui C-H, Camitta B, Pullen J: Prospective analysis of TEL gene rarrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study Journal of Clinical Oncology, 2008; 26:2186-21912008
Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Martin PL, Pullen DJ, Viswanatha D, Willman CL, Winick H, Camitta B: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors. A Children's Oncology Group study Blood, 2008; 111(12):5477-54852008
Elkin TD, Jenso SA, McNeil L, Gilbert ME, Pullen J, McComb L Religiosity and coping in mothers of children diagnosed with cancer: An exploratory analysis. J Pediatr Oncol Nursing. 2007;24:274-2782007
Heerema NA, Raimondi SC, Biegel J, Camitta BM, Cooley LD, Gaynon PS, Hirsch B, Magenis HE, McGavran L, Patil S, Pettenati MJ, Pullen J, Rao K, Roulston D, Schneider NR, Shuster JJ, Sanger W, Sather H, Sutcliffe MJ, van Tuinen P, Watson MS, Carroll AJ: Specific extra chromosomes occur in modal number dependent pattern in pediatric acute lymphoblastic leukemia Genes, Chromosomes and Cancer, 2007; 46(7):684-6932007
Schultz KR, Pullen J, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Gaynon PS, Camitta BM: Risk and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group and Children's Cancer Group Blood, 2007; 109:926-9352007
Chauvenet A, Martin P, Devidas M, Bell B, Kurtzberg J, Pullen J, Pettenati M, Carroll AJ, Shuster J, Camitta B: Anti-metabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: Pediatric Oncology Group study 9201 Blood, 2007; 110:1105-11112007
Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris MB, Shuster JJ: Allergic reactions to E.coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group study J Pediatr Hematol Oncol, 2007; 29(9):627-6322007
Barredo JC, Devidas M, Lauer SJ, Billett A, Marymont MA, Pullen J, Camitta B, Winick N, Carroll W, Ritchey A Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS irradiation: A Pediatric Oncology Group Study. J Clin Onco1, 2006;24(19):3142-31492006
Bomgaars LR, Megason GC, Pullen J, Langevin AM, Kuhn J, Bernstein M, Blaney SM: Phase I trial of MGI 114 in pediatric patients with solid tumors Pediatric Blood & Cancer, 2006; 47(2):163-1682006
Mehta PA, Davies SM, Kumar A, Devidas M, Lee S, Wilke T, Elliott J, Villaneuva J, Pullen J, Zewge Y, Filipovich A: Perforin polymorphism A91V and susceptibility to childhood acute lymphoblastic leukemia Leukemia, 2006; 20(9):1539-15412006
Sutcliffe MJ, Shuster JJ, Sather HN, Camitta BM, Pullen J, Schultz KR, Borowitz MJ, Gaynon PS, Carroll AL, Heerema NA High concordance from independent studies by the Children’s Cancer Group and Pediatric Oncology Group associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI standard risk B-precursor acute lymphoblastic leukemia: A Children’s Oncology Group initiative. Leukemia. 2005;19:734-7402005
Savasan S, Buck S, Ozdemir O, Hamre M, Asselin B, Pullen J, Ravindranath Y: Evaluation of cytotoxicity by flow cytometric drug sensitivity assay in childhood T-cell acute lymphobalstic leukemia Leuk Lymphoma, 2005; 46(6) 833-8412005
Sutcliffe MJ, Shuster JJ, Sather HN, Camitta BM, Pullen J, Schultz KR, Borowitz MJ, Gaynon PS, Carroll AL, Heerema NA: High concordance from independent studies by the Children’s Cancer Group and Pediatric Oncology Group associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI standard risk B-precursor acute lymphoblastic leukemia: A Children’s Oncology Group initiative Leukemia, 2005; 19:734-7402005
Stoppelbein L, Greening L, Jordan SS, Elkin TD, Moll G, Pullen J: Factor analysis of the Pediatric Symptom Checklist with a chronically ill pediatric population J Dev Behav Pediatr, 2005; 26(5):349-3612005
Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection: A report from the Children's Oncology Group Cytometry & Clin Cytom, 2005; 68(1):18-242005
Whitehead VM, Shuster JJ, Vuchich M-J, Mahoney DH, Lauer SJ, Payment C, Kock PA, Cooley LD, Look At, Pullen DJ, Camitta B: Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study Leukemia, 2005; 19:533-5362005
Diccianni MB, Yu J, Meppelink G, de Vries M, Shao L-E, Gebauer G, Shih H, Roberts W, Kilcoin N, Pullen J, Carson DA, Yu AL 3-amino thioacridone inhibits DNA synthesis and induces DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in p-16 dependent manner. J Exp Therapeutics Oncology. 2004;4:223-2372004
Heerema NA, Harbott J, Galimberti S, Camitta B, Gaynon P, Janka-Schaub G, Kamps W, Basso G, Pui C, Schrappe M, Auclerc M. Carroll A, Conter V, Harrison C, Pullen J, Raimondi S, Richards S, Riehm H, Sather H, Shuster J, Silverman L, Valsecchi M, Arico M: Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are non random and may be associated with outcome Leukemia, 2004; 18:693-7022004
Borowitz MJ, Pullen DJ, Shuster J, Viswanatha D, Montgomery K, Willman CL, Camitta B: Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: Relation to other factors. A Children's Oncology Group study Leukemia, 2003; 17:1566-15722003
Applegate H, Webb P, Elkin TD, Neul S, Drabman R, Moll, Jr G, Pullen J, Smith MG, Iyer R, Megason G: Improving Parent Participation at Pediatric Diabetes and Sickle Cell Appointments Using a Brief Intervention Children's Health Care , 2003; 32(2): 125-1362003
Pui C-H, Chessells JM, Camitta B, Baruchel A, Biondi A, Boyett JM, Carroll A, Eden OB, Evans WE, Gadner H, Harbott J, Harms DO, Harrison CJ, Harrison PL, Heerema N, Janka-Schaub G, Kamps W, Masera G, Pullen J, Raimondi SC, Richards S, Riehm H, Sallan S, Sather H, Shuster J, Silverman LB, Valsecchi MG, Vilmer E, Zhou Y, Gaynon PS, Schrappe M: Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements Leukemia, 2003; 17:700-7062003
Winter SS, Sweatman J, Shuster JJ, Link MP, Amylon MD, Pullen J, Camitta BM, Larson RS: Bone marrow stroma-supported culture of T-lineage acute lymphoblastic leukemia cells predicts treatment outcome in children: A Pediatric Oncology Group study Leukemia, 2002; 16(6):1121-11262002
Shuster J, Link M, Camitta B, Pullen J, Behm F: Minimax two-stage designs with applications to tissue banking case-control studies Statistics in Medicine, 2002; 21(17):2479-24932002
Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondo A, Harms DO, Vilmer E, Schrappe M, Camitta B, Masera G, Riehm H, Harbott J, Harrison C, Eden OB, Carroll A, Heerema N, Pullen J, Sather H, Shuster J Outcome of treatment of childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359(9321):1909-19152002
Shao L, Diccianni MB, Tanaka T, Gribi R, Yu AL, Pullen DJ, Camitta BM, Yu J: Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication Cancer Res, 2001; 64:7333-73382001
Whitehead VM, Payment C, Cooley L, Lauer SJ, Mahoney DJ, Shuster JJ, Vuchich MJ, Bernstein ML, Look AT, Pullen DJ, Camitta BM: The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study Leukemia, 2001; 15(7):1081-10882001
Lauer SJ, Shuster JJ, Mahoney DH, Winick N, Toledano S, Munoz L, Kiefer G, Pullen J, Steuber CP, Camitta BM: A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group phase III randomized trial Leukemia, 2001; 15:1038-10452001
Shah SJ, Taub JW, Witt TL, Pollock BH, Ding BC, Moore DS, Amylon M, Pullen J, Ravindranath Y, Matherly LH: Relationship of p15 and p16 gene altrations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukemia Br J Haematol, 2001; 113:746-7562001
Omura-Minamisawa M, Diccianni MB, Batova, Chang RC, Bridgeman LJ, Yu J, de Wit E, Kung FH, Pullen J, Camitta B, Yu AL: In vitro sensitivity of T-cell lymphoblastic leukemia to UCN-01 (7-Hydroxystaurosporine) is dependent on p16 protein status: A Pediatric Oncology Group study Cancer Res, 2000; 60:6573-65762000
Harris MB, Shuster JJ, Pullen J, Borowitz MJ, Carroll AJ, Behm FG, Camitta BM, Land VJ: Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: A Pediatric Oncology Group study Leukemia, 2000; 14:1570-15762000
Schneider NT, Carroll AJ, Shuster JJ, Pullen J, Link MP, Borowitz MJ, Camitta BM, Katz JA, Amylon MD: New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia. A Pediatric Oncology Group report of 343 cases Blood, 2000; 96:2543-25492000
Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchen A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui C-H, Masera G, Conter V, Riehm H, Heerema N, Sallan S, Auclerc MF, Pullen J, Shuster J, Carroll A, Raimondi S, Richards S: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. International Leukemia Working Group New Engl J Med, 2000; 342: 998-10062000
Kaleem Z, Shuster JJ, Carroll AJ, Borowitz MJ, Pullen DJ, Camitta BM, Zutter MM, Watson MS: Acute lymphoblastic leukemia with an unusual t(8;14)(q11.2;q32): A Pediatric Oncology Group study Leukemia, 2000; 14:238-2402000
Omura-Minamisawa M, Dicciana MB, Batova A, Chang R, Bridgeman LJ, Yu J, Pullen J, Bowman WP, Yu A: Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia Clin Cancer Res, 2000; 6:1219-12282000
Laver BH, Barredo JC, Amylon M, Schwenn M, Kurtzberg J, Camitta BM, Pullen J, Link MP, Borowitz B, Ravindranath Y, Murphy SB, Shuster J: Effects of cranial radiation in children with high risk T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group Report Leukemia, 2000; 14:369-3732000
Pollock B, DeBaun M, Camitta B, Shuster J, Ravindranath Y, Pullen J, Land VJ, Mahoney D, Lauer S, Murphy SB: Ethnic differences in the survival of childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study J Clin Oncol, 2000; 18:813-8232000
Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BM: Long term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994 Leukemia, 2000; 14:2276-22852000
Batova A, Diccianni MB, Yu J, Bridgeman L, Pullen J, Amylon MJ, Yu AL Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro. Cancer Research. 1999; 59:1492-14971999
Pullen J, Shuster JJ, Link M, Borowitz M, Amylon M, Carroll D, Land V, Look AT, McIntyre B, Camitta B Significance of commonly used prognostic factors differs for children with T-cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. Leukemia. 1999; 13:1696-17071999
Navid F, Mosijczuk AD, Head DR, Borowitz MJ, Carroll AJ, Brandt MJ, Link MP, Rozans MK, Thomas GA, Schwenn MR, Shields DJ, Vietti TJ, Pullen DJ Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: The Pediatric Oncology Group experience. Leukemia. 1999;13:135-1411999
Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Jirtzbert J, Desai S, Camitta , Muphy SB Intensive high dose asparaginase consolidation improves survival for pediatric patients with T-cell acute lymphoblastic leukemia and advanced stage lymphoblastc lymphoma: Pediatric Oncology Group Study 8704 Leukemia. 1999;13:335-3421999
Shuster JJ, Camitta BM, Pullen J, Borowitz MJ, Carroll AJ, Look AT, Mahoney DH, Lauer SJ, Land VJ Identiication of newly diagnosed children with acute lymphocytic leukemia at high risk for relapse. Cancer Research Therapy and Control. 1999;9:101-1071999
Rubnitz JE, Camitta VM, Mahmoud H, Raimondi SC, Carroll AJ Borowitz MJ, Shister JJ, Link MP, Pullen DJ, Downing JR Behm FG, Pui C-H Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3). Journal of Clinical Oncology. 1999;17:191-1961999
Borowitz MJ, Rubnitz J, Nash M, Pullen DJ, Camitta B Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL. A Pediatric Oncology Group study. Leukemia. 1998;12:1764-17701998
Whitehead VM, Buchich M-J, Lauer SJ, Mahoney D, Shuster JJ, Payment C, Cock A, Adabutu JJ, Bowen T, Kamen BA, Ravindranath Y, Emami A, Look AT, Beardsley GP, Pullen DJ, Camitta BM Accumulation of methotrexate polyglutamates, ploidy and trisomy of chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Leukemia and Lymphoma. 1998;31:507-5191998
Lauer SJ, Camitta BM, Leventhal BG, Mahoney D, Shuster JJ, Kiefer G, Pullen J, Steuber CP, Carroll AJ, Kamen B Intensive alternating drug pairs for treatment of infant acute lymphoblastic leukemia. A Pediatric Oncology Group study. J Pediat Hematol/Oncol. 1998;20(3):229-2331998
Zhang L, Taub JW, Williams M, Wong SC, Hukku B, Pullen J, Ravindranath Y, Matherly L Reduced folate carrier gene expression in chlidhood acute lymphoblastic leukemia: Relationship to immunophenotype and ploidy. Clin Ca Research. 1998;4:2169-21771998
Shuster JJ, Wacker P, Pullen J, Humbert J, Land VJ, Mahoney DJ, Lauer S, Look AT, Borowitz MJ, Carroll AJ, Camitta BM Prognostic significance of gender in childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol, 1998;16(8):2854-28631998
Harris MB, Shuster JJ, Pullen DJ, Borowitz MJ, Carroll AJ, Behm FG, Land VJ Consolidation therapy with anti-metabolite based therapy in standard risk acute lymphocytic leukemia of childhood: A Pediatric Oncology group study. J Clin Oncol, 1998;16(8):2840-28471998
112. Hunger SP, Fall MZ, Camitta BM, Carroll AJ, Link MP, Lauer SJ, Mahoney DH, Pullen DJ, Shuster JJ, Cleary ML Detection of minimal residual disease by amplification of E2A-PBX1 chimeric transcripts at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): A Pediatric Oncology Group study. Blood. 1998;91:1021-10281998
Geiser PW, Chang MN, Rao PV, Shuster JJ, Pullen J Modeling cure rates using the Compertz model with covariate information. Statist Med. 1998;17:831-8391998
Whitehead VM, Vuchich M-J, Cooley L, Lauer SJ, Mahoney DH, Shuster JJ, Payment C, Bernstein ML, Akabutu JJ, Bower T, Kamen BA, Watson MS, Look AT, Pullen DJ, Camitta B Translocations involving chromosome 12p11-13, methotrexate metabolism and outcome in childhood B-lineage acute lymphoblastic leukemia. Clin Cancer Res. 1998;4:183-1881998
Alvarado CS, Austin GE, Borowitz MJ, Shuster JJ, Carroll AJ, Austin ED, Zhou M, Zaki SR, Pullen J Myeloperoxidase gene expression in infant leukemia: A Pediatric Oncology Group study. Leukemia and Lymphoma. 1998;29:145-1601998
Diccianni MB, Batova A, Yu J, Vu T, Pullen J, Amylon M, Pollock B, Yu A Shortened survival after relapse in T cell acute lymphoblastic leukemia for patients with p16/p15 deletions. Leukemia Research. 1997;21(6):549-5581997
Batova A, Diccianni MB, Yu JC, Norori T, Link MP, Pullen J, Yu AL Frequent and selective methylation of p15 in addition to p16 deletion in T-cell ALL. Cancer Research. 1997;57:832-8361997
Maloney KW, Rubnitz JE, Cleary ML, Frankel LW, Hakami N, Link MP, Pullen DJ, Hunger SP Lack of ETV6 (TEL) gene rearrangements of p16INK4A/p15INK4B homozygous gene deletions in infant acute lymphoblastic leukemia. Leukemia. 1997;11:979-9831997
Matherly LH, Taub JW, Wong SC, Simpson P, Ekizian R, Buck S, Amylon M, Pullen J, Camitta B, Ravindranath Y Increased frequency of heterogeneous expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphocytic leukemia in children. Blood. 1997;90(2):578-5891997
Borowitz MJ, Shuster J, Carroll AJ, Look AT, Camitta B, Mahoney D, Lauer SJ, Pullen DJ: Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor ALL. A Pediatric Oncology Group study. Blood. 1997; 89(11):3960-39661997
Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen J, Camitta BM, Pui C-H, Downing JR, Behm FG Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: A Pediaric Oncology Group study. Blood. 1997;89(4):1143-11461997
Camitta BM, Pullen J, Winick N, Murphy S Biology and treatment of acute lymphocytic leukemia in children. Seminars in Oncology. 1997;24(1):83-911997
Frankel LS, Ochs J, Shuster JJ, Dubowy R, Bowman WP, Hockenberry-Eaton M, Borowitz M, Carroll AJ, Steuber CP, Pullen DJ Therapeutic trial for infant acute lymphoblastic leukemia: The Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol/Onco. 1997; 19(1);35-421997
Graham ML, Shuster JJ, Kamen BA, Land VJ, Borowitz MJ, Camitta B, Cheo DL,
Harrison MP, Leventhal BG, Pinkel DP, Pullen DJ, Steuber P, Whitehead VM Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: A Pediatric Oncology Group study. Clin Cancer Res. 1996;2:331-337
1996
Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn E, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Underleider R A uniform approach to risk-classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18-241996
Martin PL, Look AT, Schnell S, Harris MB, Pullen J, Shuster JJ, Carroll AJ, Pettenati MJ, Rao N Comparison of fluorescence in situ hybridization, cytogenetic analysis and DNA index analysis to detect chromosomes 4 and 10 aneuploidy in pediatric acute lymphoblastic leukemia A Pediatric Oncology Group study. J Pediatr Hematol/Oncol. 1996;18(2):113-1211996
Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J, Link M, Head D, Carroll A, Berard C, Murphy S Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved cell lymphoma: A Pediatric Oncology Group study. J Clin Oncol. 1996;14(4):1252-12611996
Mahmoud HH, Schwartz C, Shuster J, Pui CH, Behm F, Amylon M, Raimondi S, Borowitz M, Link M, Pullen J, Camitta B, Hakami N, Crist W, Carroll A The (11;19) translocation is associated with poor outcome in infants with acute lymphoblastic leukemia. A collaborative study of the POG and SJCRH. Med Ped Oncol. 1994;23:199-2041994
Land VJ, Shuster JJ, Crist WM, Ravindranath Y, Harris MB, Krance RA, Pinkel D, Pullen DJ: Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol. 1994;12:1939-¬19491994
Rubnitz JE, Link MP, Shuster JJ, Carroll AJ, Hakami N, Frankel LS, Pullen DJ, Cleary ML Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood, 1994;84:570¬5731994
Downing JR, Head DR, Raimondi SC, Carroll AJ, Curcio-Brint AM, Motroni TA, Hulshof MG, Pullen DJ, Domer PH The der(11) encoded MLL-AF-4 fusion transcript is consistently detected in t(4;11)(q21;q23) containing acute lymphoblastic leukemia. Blood. 1994;83:330-3351994
Smith JC, Megason GC, Iyer RV, Andrew ME, Pullen DJ Clinical characteristics of children with hereditary hemolytic anemias and aplastic crisis: A 7 year review. Southern Med J. 1994;87(7):702-7081994
Pettenati MJ, Rao N, Wofford M, Shuster JJ, Pullen DJ, Steuber CP, Carroll AJ Presenting characteristics of trisomy 8 as the primary cytogenetic abnormality associated with childhood acute lymphoblastic leukemia -A Pediatric Oncology Group study. Cancer Genet Cytogenet. 1994;75:6-101994
Smith M speaking for Arthur D, Camitta B, Crist W, Gaynon P, Gelber R, Heerema N, Korn E, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallan S, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R Towards a more uniform approach to risk-classification and treatment assignment for children with acute lymphoblastic leukemia. Presented, May 1994, Dallas TX. Amer Soc Clin Oncol.1994; Educational Book, pgs 124-1301994
Pui C-H, Carroll AJ, Raimondi SC, Shuster JJ, Crist WM, Pullen DJ Childhood ALL with the t(4;11)(q21;q23):An update. Blood. 1994;83(8):2384-23851994
Duffner P, Burger P, Cohen M, Sanford R, Krischer J, Elterman R, Aronin P, Pullen J, Horowitz M, Parent A, Kun L Desmoplastic infantile gangliogliomas: An approach to therapy. Neurosurgery. 1994;34(4):583-5891994
Kato GJ, Quddus FF, Leventhal BG, Shuster JJ, Boyett J, Behm FG, Pullen DJ, Borowitz JM, Whitehead VM, Crist WM Glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood. 1993;82(8):2304-23091993
Watson MS, Carroll AJ, Shuster JJ, Steuber CP, Borowitz MJ, Behm FG, Pullen DJ, Land VJ Trisomy 21 in childhood acute lymphoblastic leukemia (ALL). A Pediatric Oncology Group study. Blood. 1993;82(10):3098-31021993
Shuster JJ, Carroll AJ, Look TA, Pui CH, Land VJ, Jackson J, Pullen DJ, Steuber CP, Crist WM Management of cytogenetic data in multi-center leukemia trials. Computer Methods and Programs in Biomedicine. 1993;40:269-277, 19931993
Koehler M, Behm F, Shuster J, Crist W, Borowitz M, Look AT, Head D, Carroll AJ, Land V, Steuber P, Pullen DJ Transitional pre-B-cell acute lymphoblastic leukemia of childhood is associated with prognostically favorable clinical features and an excellent outcome. A Pediatric Oncology Group study. Leukemia. 1993;7(12):2064-20681993
Borowitz MJ, Hunger SP, Carroll AJ, Shuster JJ, Pullen DJ, Steuber CP, Cleary ML Predictability of the t(1;19)(q23;q13) from surface antigen phenotype: Implications for screening cases of childhood ALL for molecular analysis. A Pediatric Oncology Group study. Blood. 1993;82(4):1086-10911993
Pui C-H, Raimondi SC, Borowitz MJ, Land VJ, Behm FG, Pullen DJ, Hancock ML, Shuster JJ, Steuber CP, Crist WM, Civin CI, Carroll AJ Acute lymphoblastic leukemia in children with Down Syndrome. J Clin Oncol. 1993;11:1361-13671993
Lauer SJ, Camitta B, Leventhal B, Mahoney D, Shuster JJ, Adair S, Casper J, Civin C,
Graham M, Kiefer G, Pullen J, Steuber P, Kamen B Intensive alternating drug pairs for treatment of high risk childhood acute lymphoblastic leukemia: A Pediatric Oncology Group pilot study. Cancer. 1993;71:2854-2861
1993
Pullen J, Boyett J, Shuster J, Crist W, Land V, Frankel L, Iyer R, Backstrom L, van Eys J, Harris M, Ravindranath Y, Sullivan M Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol, 1993;11(5):839-8491993
Bash RO, Crist WM, Shuster JJ, Link MP, Amylon M, Pullen J, Buchanan GR, Smith RG, Baer R Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alteration at the TAL1 locus, A Pediatric Oncology Group study. Blood. 1993;81 (8):2110-21171993
Graham ML, Shuster JJ, Kamen BA, Cheo DL, Harrison MP, Leventhal BG, Pullen DJ, Whitehead VM Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: a Pediatric Oncology Group pilot study. Cancer Chemother Pharmacol, 1992; 31:271-2221992
Whitehead VM, Vuchich MJ, Lauer S, Mahoney D, Carroll AJ, Shuster JJ, Esseltine DL, Payment C, Look TA, Akabutu J, Bowen T, Taylor LT, Camitta B, Pullen DJ Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood. 1992;80(5):1316-13231992
Falletta JM, Shuster JJ, Crist WM, Pullen DJ, Borowitz MJ, Wharam M, Petterson R, Foreman E, Vietti TJ Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: A Pediatric Oncology Group study. Leukemia. 1992;6(6):541-5461992
Krance RA, Raimondi SC, Dubowy R, Estrada J, Borowitz M, Behm F, Land VJ, Pullen J, Carroll AJ t(12;17)(p13;q21) in early pre-B acute lymphoid leukemia. Leukemia. 1992;6(4):251-2551992
Abshire TC, Buchanan GR, Jackson JF, Shuster JJ, Brock B, Head D, Behm F, Crist WM, Link MP, Borowitz M, Pullen DJ Serial morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. Leukemia. 1992;6:357-3621992
Mahmoud H, Carroll AJ, Behm F, Raimondi S, Shuster J, Borowitz M, Land V, Pullen DJ, Vietti TJ, Crist W The non-random dic(9;12) translocation is exclusively associated with the B-progenitor phenotype and confers an excellent prognosis. Leukemia. 1992;6(7):703-7071992
Crist W, Shuster J, Look T, Borowitz M, Behm F, Bowman P, Frankel L, Pullen J, Steuber P, Amylon M, Link M, Land V Current results of immunophenotype-, age¬and leukocyte-based therapy for children with acute lymphoblastic leukemia. A Pediatric Oncology Group study. (Presented at Fifth International Symposium on Therapy of Acute Leukemias, Rome, Italy, November 1-6, 1991.) Leukemia 6:162-167, 1992 Leukemia. 2991;6:162-1671992
Harris MB, Shuster JJ, Carroll A, Look AT, Borowitz MJ, Crist WM, Nitschke R, Pullen J, Steuber CP, Land VF Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure. A Pediatric Oncology Group study. Blood. 2991;79(12):3316-33241992
Watson MS, Land VJ, Carroll AJ, Pullen J, Borowitz MJ, Link MP, Amylon M, Behm FG t(2;14)(p13;q32): A recurring abnormality in lymphocytic leukemia. Cancer Genet Cytogenet. 1992;58:121-1241992
Trueworthy R, Shuster J, Look T, Crist W, Borowitz M, Carroll A, Frankel L, Harris M, Wagner H, Haggard M, Misijczuk A, Pullen J, Steuber P, Land V Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol. 1992;10(4):606-6131992
Sullivan M, Brecher M, Ramirez I, Ragab A, Hvizdala E, Pullen J, Shuster J, Berard C High-dose cyclophosphamide --high-dose methotrexate with coordinated intrathecal therapy for advanced non-lymphoblastic non-Hodgkin's lymphoma of childhood: Results of a POG study. Am J Ped Hem Onc. 1991;13(3):288-2951991
Krance RA, Newman EM, Ravindranath Y, Harris MB, Brecher M, Wimmer R, Shuster JJ, Land VJ, Pullen J, Crist W, Pinkel E A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front" in continuation therapy for chldhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study. Cancer. 1991;67(3):550-5561991
Cerezo L, Shuster JJ, Pullen J, Brock B, Borowitz MJ, Falletta JM, Crist WM, Head DR Laboratory correlates and prognostic significance of granular acute lymphoblastic leukemia in children. A Pediatric Oncology Group study. Am J Clin Pathol. 1991;95(4):526-5311991
Russo C, Carroll A, Kohler S, Borowitz M, Amylon M, Homans A, Kedar A, Shuster J,
Land V, Crist W, Pullen J, Link M The Philadelphia chromosome and monosomy 7 in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group study. Blood. 1991;77(5):1050-1056
1991
Pui C-H, Frankel LS, Carroll AJ, Raimondi SC, Shuster JJ, Head DR, Crist WM, Land VJ, Pullen DJ, Steuber CP, Behm FG, Borowitz MJ Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with t(4;11)(q21;q23). A collaborative study of 40 cases. Blood. 1991;77(3):440-4471991
Pui C-H, Carroll AJ, Head D, Raimondi SC, Shuster JJ, Crist WM, Link MP, Borowitz MJ, Behm FG, Land VJ, Nash MG, Pullen DJ, Look AT Near-triploid and near tetraploid acute lymphoblastic leukemia of childhood. Blood. 1991;76(3):590-5961991
Carroll AJ, Crist WM, Link MP, Amylon MD, Pullen DJ, Ragab AH, Buchanan GR,
Wimmer RS, Vietti TJ The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood. 1990;76(6):1220-1224
1990
Crist W, Carroll A, Shuster J, Jackson J, Head D, Borowitz M, Behm F, Link M, Steuber P, Ragab A, Hirt A, Brock B, Land V, Pullen J Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome. Blood. 1990;76:489-4941990
Borowitz M, Shuster JJ, Civin CI, Carroll AJ, Look AT, Behm FG, Land VJ, Pullen DJ, Crist WM Prognostic significance of CD34 expression in childhood B¬precursor acute lymphocytic leukemia. A Pediatric Oncology Group study. J Clin Oncol. 1990; 8(8):1389-13981990
Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti RJ, Look AT, Mahoney D, Ragab A, Pullen DJ, Land VJ Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13). A Pediatric Oncology Group study. Blood. 1990; 76(1):117-1121990
Sullivan MP, Pullen J, Crist W, Head D, Cerezo L, Brecher M, Ramirez I, Sabio H,
Borowitz M, Shuster J, Murphy S Clinical and biological heterogeneity of childhood B-cell leukemia: Implications for clinical trials. Leukemia. 1990;4(1):6-11
1990
Jackson JF, Boyett J, Pullen J, Brock B, Patterson R, Land V, Borowitz M, Head D, Crist W Favorable prognosis associated with hyperdiploidy in children with acute lymphocytic leukemia correlates with extra chromosome 6. Cancer. 1990;66(6):1183-11891990
Pui C-H, Carroll AJ, Raimondi SC, Land VJ, Crist WM, Williams DL, Pullen DJ,
Borowitz MJ, Behm FG, Look AT Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid and hypodiploid <45 line. Blood. 1990;75(5):1170-1177
1990
Shuster JJ, Falletta JM, Pullen DJ, Crist WM, Humphrey GB, Dowell BL, Wharam MD, Borowitz M: Prognostic factors in childhood T-cell acute lymphoblastic leukemia. Blood. 1990;75(1):166-1731990
Crist W, Boyett J, Jackson J, Vietti T, Borowitz M, Chauvenet A, Winick N, Ragab A, Mahoney D, Head D, Iyer R, Wagner H, Pullen J: Prognostic importance of the pre-B cell immunophenotype and other presenting features in B-lineage childhood lymphocytic leukemia. Blood. 1989;74(4):1252-12591989
van Eys J, Berry D, Crist W, Doering E, Fernbach D, Pullen J, Shuster J Treatment intensity and outcome for children with acute lymphocytic leukemia of standard risk. A Pediatric Oncology Group study. Cancer. 1989;63:1466-14711989
Dubansky AS, Boyett J, Falletta J, Mahoney D, Land V, Pullen J, Buchanan G The rarity of isolated severe thrombocytopenia in acute lymphoblastic leukemia. A Pediatric Oncology Group study. Pediatrics. 1989;84:1068-10711989
van Eys J, Berry D, Crist W, Doering E, Fernbach D, Pullen J, Shuster J, Wharam M A comparison of two regimens for high risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group study. Cancer. 1989;63(1):23-291989
Crist WM, Shuster JJ, Falletta J, Pullen DJ, Berard CW, Vietti TJ, Alvarado CS, Roper MA, Prasthofer E, Grossi CE Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: A Pediatric Oncology Group study. Blood. 1988;72(6):1891-18971988
Nuss R, Kitchingman G, Cross A, Zipf TF, Antoun GR, Bernstein I, Behm F, Pullen DJ, Crist W, Mirro J, Goorha R T cell gene rearrangements in B-precursor acute lymphoblastic leukemia correlate with age and the stage of B cell differentiation. Leukemia. 1988;2(1):722-7271988
Hurwitz CA, Loken MR, Graham ML, Karp JE, Borowitz MF, Pullen DJ, Civin CI Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood. 1988;72(1):299-3071988
Crist W, Pullen J, Boyett J, Falletta J, van Eys J, Borowitz M, Jackson J, Dowell B, Russell C, Quddus F, Ragab A, Vietti T Acute lymphoid leukemia in adolescents: Clinical and biologic features predict a poor prognosis - A Pediatric Oncology Group study. J Clin Oncol. 1988; 6:34-431988
Carroll AJ, Raimondi SC, Williams DL, Behm FG, Borowitz M, Castleberry RP, Harris MB, Patterson RB, Pullen DJ, Crist WM tdic (9;12): A nonrandom chromosome abnor¬mality in childhood B-cell precursor acute lymphoblastic leukemia (ALL): A Pediatric Oncology Group study. Blood. 1987;70(6):1962-19651987
Morabito F, Prasthofer EF, Pullen DJ, Mahoney D, Downing JR, Crist WM, Grossi CE Analysis of surface antigen profile, TdT expression, and T cell receptor gene rearrangement for maturational staging of leukemic T cells. A Pediatric Oncology Group study. Leukemia. 1987;1(6):514-5171987
Dowell BL, Borowitz MJ, Boyett JM, Pullen DJ, Crist WM, Quddus FF, Russell EC,
Falletta JM, Metzgar RS Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. A Pediatric Oncology Group study. Cancer, 1987;59:2020-2026
1987
van Eys J, Berry DM, Crist W, Doering EJ, Fernbach DJ, Pullen J, Shuster J Effect of Trimethoprim/Sulfamethoxazole prophylaxis on outcome of childhood acute lymphocytic leukemia. A Pediatric Oncology Group study. Cancer. 1987;59(1):19-231987
Steinberg MH, Adams JG, Morrison WT, Pullen DJ, Abney R, Ibrahim A, Rieder RF Hemoglobin Mississippi (B44ser-cys): Studies of the Thalassemic phenotype in a mixed heterozygote with B+-Thalassemia. J Clin Inves. 1987; 79:826-8321987
van Eys J, Pullen J, Head D, Boyett J, Crist WM, Falletta J, Humphrey GB, Jackson J, Riccardi V, Brock B The French-American-British (FAB) classification of leukemia. The Pediatric Oncology Group experience with lymphocytic leukemia. Cancer, 1986;57(5):1046-10511986
Head DR, Borowitz M, Cerezo L, Craven CM, Brock BL, Boyett JM, Pullen DJ, Crist WM, Falletta J, Humphrey GB Acid phosphatase positivity in childhood acute lymphocytic leukemia. Amer J Clin Pathol. 1986;86(5):650-6531986
Crist W, Boyett J, Pullen J, van Eys J, Vietti T Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents. A Pediatric Oncology Group study. Presented at SIOP Workshop, October 7-8, 1985, Rome, Italy. Med Pediatr Oncol. 1986;14:135-1391986
Crist W, Pullen J, Boyett J, Falletta J, van Eys J, Borowitz M, Jackson J, Dowell B, Frankel L, Quddus F, Ragab A, Vietti T Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in infants: A Pediatric Oncology Group study. Blood, 1986;67(1):135-1401986
Borowitz MJ, Dowell BL, Boyett JM, Pullen DJ, Crist WM, Quddus FF, Falletta JM,
Metzgar RS Clinicopathologic aspects of E-rosette negative T cell acute lymphocytic leukemia. A Pediatric Oncology Group study. J Clin Oncol. 1986;4(2):170¬177
1986
Crist W, Rivera G, Pullen J, Weinstein H The leukemias of childhood. Hematology 1985: Education Program of the American Society of Hematology, pages 48-541985
Quddus FF, Leventhal BG, Boyett JM, Pullen DJ, Crist WM, Borowitz MJ Glucocorticoid receptors in immunologic subtypes of childhood acute lymphocytic leukemia cells: A Pediatric Oncology Group study. Cancer Res. 1985;45:6482-64861985
Borowitz MJ, Dowell BL, Boyett JM, Falletta JM, Pullen DJ, Crist WM, Humphrey GB, Metzgar RS Monoclonal antibody definition of T-cell acute leukemia. A Pediatric Oncology Group study. Blood. 1985;65(4):785-7881985
Crist WM, Grossi C, Pullen J, Cooper MD Immunologic markers in childhood acute lymphocytic leukemia. Semin Oncol 12(2):105-121, 19851985
Sullivan MP, Boyett J, Pullen J, Crist W, Doering EJ, Trueworthy R, Hvizdala E, Ruymann R, Steuber CP Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded). Cancer. 1985;55(2):323-3261985
Humphrey GB, Blackstock R, Falletta JM, Metzgar RS, Richie ER, Pullen DJ, Boyett JM, Shuster JJ, Roper MA, Russell EC, Mahoney DH, Ragab AH An analysis of the presence of Fc receptors on bone marrow lymphoblasts in acute lymphoblastic leukemia. Cancer. 1985;(8):1995-20001985
Cerezo L, Head DR, Pullen J, Humphrey B The prevalence of hand-mirror cells in acute
myeloblastic and lymphoblastic leukemia.
Amer J Clin Pathol. 1984;81:355-357
1984
Falletta J, Boyett J, Pullen J, Crist W, Dowell B, Roper M, Humphrey B, Metzgar R,
Cooper M, van Eys J Clinical and phenotype features of childhood ALL by race and Spanish origin. Presented International Workshop on the influence of the Environment on Leukemia and Lymphoma Subtypes. Workshop Proceedings, Raven Press, vol 27, pp 191-195, 1984
1984
Crist W, Boyett J, Roper M, Pullen J, Metzgar R, van Eys J, Ragab A, Starling K, Vietti T,
Cooper M Pre-B cell leukemia responds poorly to treatment: A Pediatric Oncology Group study. Blood 63, 1984;2):407-414. Selected for inclusion in Year Book of Cancer, 1985, RC Hickey, GF Saunders, RL Clark and RW Cumley (eds), Year Book Medical Publishers, Inc, Chicago, pp 175-176
1984
Frankel LS, Wang YM, Shuster J, Nitschke R, Doering EJ, Pullen J High dose methotrexate in the maintenance of remission in acute lymphocytic leukemia: A Pediatric Oncology Group pilot study. J Clin Oncol. 1983;1(12):804-8091983
Roper M, Crist WM, Metzgar R, Ragab AH, Smith S, Starling K, Pullen J, Leventhal B, Bartolucci AA, Cooper MD Monoclonal antibody characterization of surface antigens in childhood T-cell lymphoid malignancies. Blood. 1983;61(5):830-8371983
Jackson JF, Pullen J, Williams DL, Bowman P, Roper M, Carroll AJ, Vogler L, Crist W, Starling KA, van Eys J 982 Cytogenetics of B-cell lineage acute lymphocytic leukemias of childhood. The Lancet II. 1982;(8311):13341982
Komp DM, Fernandez CH, Falletta JM, Ragab AH, Humphrey GB, Pullen DJ, Moon T, Shuster J CNS prophylaxis in acute lymphoblastic leukemia - comparison of two methods. A Southwest Oncology Group study. Cancer. 1982;50:1031-10361982
Pullen DJ, Sullivan MP, Falletta JM, Boyett JM, Humphrey GB, Starling KA, Land VJ, Dyment PG, Vats T, Duncan MH Modified LSA2-L2 treatment in 53 children with E-rosette positive T-cell leukemia: Results and prognostic factors. (A Pediatric Oncology Group study.) Blood. 1982;60:1159-11681982
Sullivan MP, Ramirez I, Pullen J, Moore T, Doering EJ, Falletta JM, Trueworthy R, Chen T Use of Cytosar in pediatric non-Hodgkin's lymphoma. Proceedings Upjohn Cytosar Symposium, December, 19811981
Nitschke R, Starling K, Lui VKS, Pullen J Doxorubicin and cisplatin therapy in children with neuroblastoma resistant to conventional therapy: A Southwest Oncology Group study. Cancer Treat Rep. 1981;65:1105-11081981
Pullen DJ, Falletta JM, Crist WM, Vogler LB, Dowell B, Humphrey GB, Blackstock R, van Eys J, Cooper MD, Metzgar RS, Meydrech EF Southwest Oncology Group experience with immunological phenotyping in acute lymphocytic leukemia of childhood. Presented NCI conference: Cell Markers in Acute Leukemia, 3/5/80. Bethesda, Maryland. Cancer Res. 1981;41:4802-48091981
Vogler LB, Crist WM, Sarrif AM, Pullen DJ, Bartolucci AA, Falletta JM, Dowell B,
Humphrey GB, Blackstock R, van Eys J, Metzgar RS, Cooper MD 1981 An analysis of clinical and laboratory features of acute lymphocytic leukemias with emphasis on 35 children with pre-B cell leukemia. Blood. 1981;58(1):135-140
1981
Berry DH, Fernbach D, Herson J, Pullen J, Sullivan M, Vietti T Comparison of prednisone, vincristine, methotrexate and 6-mercaptopurine vs 6-mercaptopurine and prednisone maintenance therapy in childhood acute leukemia. A Southwest Oncology Group Study. Cancer. 1980;46:1098-11031980
Miale T, Hvizdala E, Ragab A, Pullen J, O'Brien P, McMillan C Cyclocytidine in the treatment of refractory acute childhood leukemia: A Southwest Oncology Group phase I-II study. Cancer Treat Re. 1979;63:1913-19151979
Herson J, Starling KA, Dyment PC, Humphrey GB, Pullen J, Vats T Vincristine and prednisone versus vincristine, L-asparaginase and prednisone for second remission induction of acute lymphocytic leukemia. Med Pediatr Oncol. 1979;6:317-3231979
Trueworthy RC, Sutow WW, Pullen J, Komp D, Berry DH Repeated use of L-Asparaginase in multi-drug therapy of childhood leukemia. Med Pediatr Oncol. 1978;4:91-971978
Lane DM, George SL, Komp D, Lonsdale D, Pullen J, Ragab A, Starling KA Effects of continuous or discontinuous maintenance therapy on subsequent remission maintenance in childhood leukemia. Cancer. 1977;40:2005-20091977
Cangir A, Morgan SK, Land V, Pullen J, Starling KA, Nitschke R Combination chemotherapy with adriamycin and dimethyl triazeno imidazole carboximide (DTIC) in children with metastatic solid tumors. Med Pediat Oncol. 1976;2:183-1901976
Sutow WW, Thomas D, Steuber PC, Pullen J, Vats T, Bryan JH, Morgan SK Study of cytosine arabinoside synchronization plus vincristine, prednisone and L¬asparaginase for remission induction in advanced acute leukemia in childhood. Cancer Treat Rep. 1976;60(5):591-5941976
Pullen DJ, Dyment PG, Humphrey GB, Lane DM, Ragab AH Combined chemotherapy in childhood rhabdomyosarcoma. Cancer Chemother Rep. 1975;59(2):359-3651975
Berry DH, Pullen J, George S, Vietti T, Sullivan MP, Fernbach D Comparison of prednisolone, vincristine, methotrexate and 6-mercaptopurine (POMP) vs. vincristine and prednisone induction therapy in childhood acute leukemia. Cancer. 1975;36:98-1021975
Pullen DJ, Smith R Newborn hematologic problems. J Miss State Med Assoc. 1970;11:543-5531970
Pullen DJ The fluorescent demonstration of anti-platelet antibodies in platelets and megakaryocytes. Tulane Faculty Bulletin, 19611961

Abstracts

Winick N, Martin P, Devidas M, Shuster J, Borowitz MJ, Bowman P, Larsen E, Pullen J, Hunger SP, Carroll WL, Camitta B A delayed intensification enhances continuous complete remission for patients with B-ALL when combined with intravenous methotrexate. Children's Oncology Group study POG 9904/9905 Pediatr Blood Cancer 2017; 64 (S3):0-0182017
Sitthi-Amorn J, Herrington B, Megason G, Pullen J, Gordon C, Hogan S, Koganti T, Hicks C Molecular basis of minimal residual disease in subtypes of pediatric B cell acute lymphoblastic leukemia Blood 2013; 122(21):13902013
Chen I, Harvey R, Mullighan CG, Loh ML, Devidas M, Borowitz MJ, Tasian SK, Payne-Turner D, Wharton W, Pullen J, Carroll AJ, Carroll WL, Camitta BM, Hunger S, Winick NJ, Willman CL Relationship of CRLF2 expression and outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): A report from the Children's Oncology Group J Clin Oncol 29 (abst 9505), 2011 (Platform presentation, ASCO 2011)2011
Martin PL, Winick N, Devidas M, Shuster J, Borowitz M, Willman C, Bowman WP, Larsen E, Pullen J, Hunger SP, Carroll W, Camitta BM: Outcomes with 4 hr vs 24 hr IV methotrexate infusions during intensification therapy for childhood ALL: POG 9904/9905. A Chlidren's Oncology Group study Pediatric Blood and Cancer, 2008; 51:21 (Platform presentation, American Society of Pediatric Hematology/Oncology)2008
Borowitz MJ, Devidas M, Hunger SP, Carroll WL, Linda S, Pullen DJ, Viswanatha D, Willman CL, Winick N, Camitta BM: Prognostic significance of end consolidation minimal residual disease in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group Journal of Clinical Oncology, 2008; 26:539a (Platform presentation, American Society of Clinical Oncology)2008
Winick N, Martin P, Devidas M, Shuster J, Borowitz MJ, Bowman P, Larsen E, Pullen J, Hunger SP, Carroll WL, Camitta B. Delayed intensification enhances event-free survival of children with B-precursor acute lymphoblastic leukemia who received intensification therapy with six courses of intravenous methotrexate: POG 9904/9905: A Children's Oncology Group study Blood, 2007; 110:583 (Platform presentation, American Society of Hematology)2007
Winick N, Borowitz MJ, Devidas M, Martin PL, Pullen J, Hunger SP, Carroll WL, Camitta B: Changes in the delivery of standard chemotherapeutic agents during induction affect early measure of minimal residual disease: POG 9900 for patients with B-precursor low and standard risk ALL Blood, 2006; 108:643a(Poster presentation, ASH)2006
Borowitz MJ, Devidas M, Bowman WP, Carroll WL, Chen I, Harvey R, Hunger S, Martin PJ, Pullen J, Viswanatha D, Willman CL, Winick N, Camitta B: Prognostic significance of minimal residual disease in childhood B-precursor ALL and its relation to other risk factors. A Children’s Oncology Group study Blood, 2006; 108:69a(Platform presentation, ASH)2006
Rubnitz J, Wichlan D, Devidas M, Shuster S, Kurtzberg J. Bell B, Hunger S, Chauvenet A, Pui C-H, Camitta B, Pullen J: Prospective analysis of TEL and MLL gene rearrangements in childhood acute lymphoblastic leukemia: a Children’s Oncology Group study Blood. 2006; 108:68a(Platform presentation, ASH)2006
MJ, Devidas M, Bowman WP, Larsen E, Pullen J, Camitta B: Prognostic significance of minimal residual disease in children with high risk acute lymphoblastic leukemia. A Children’s Oncology Group study Blood , 2005;160:29a(Platform presentation, ASH)2005
Mehta PA, Davies SM, Kumar A, Devidas M, Lee S, Wilke T, Elliott J, Villneuva J, Pullen J, Zewge Y, Filipovich AH: Perforin polymorphism A91V and susceptibility to childhood acute lymphoblastic leukemia Blood, 2005; 160:1453(Poster presentation, ASH)2005
Rice MA, Bell BA, Chauvenet A, Kurtzbert J, Abish SB, Pullen J, Devidas M, Camitta BM: Thrombotic and hemorrhagic events for patients on Pediatric Oncology Group protocols 9201, 9605, 9406 Blood, 2005; 106:880(Poster presentation, ASH)2005
Bell BA, Abish SB, Chauvenet A, Kurtzberg J, Pullen J, Devidas M, Shuster J, Camitta BM: A report of the event free survival for children with newly diagnosed standard risk acute lymphoblastic leukemia treated on Pediatric Oncology Group protocol 9605 Blood, 2005; 106:257a(Poster presentation, ASH)2005
Chauvenet A, Martin P, Bell B, Kurtzbert J, Pullen J, Shuster J, Devidas M, Linda J, Camitta B: Anti-metabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: Pediatric Oncology Group Study 9201 Presented at annual meeting of Pediatric Academy of Sciences, May 2005, Washington DC2005
Rodes S, Bell BA, Abish SB, Pullen J, Chauvenet A, Kurtzberg J, Devidas M, Shuster J, Camitta BM: A report of the event free survival and neurotoxixicity for children with newly diagnosed standard risk acute lymphoblastic leukemia on Pediatric Oncology Group protocol 9405 Blood, 2005; 106:882(Poster presentation, ASH)2005
Borowitz MJ, Pullen DJ, Winick N, Martin P, Bowman WP, Camitta B: Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection Blood, 2004; 104:310a(Presented, ASH)2004
Schultz KR, Pullen J, Sather H, Shuster J, Borowitz M, Heerema N, Carroll AJ, Gaynon P, Camitta B: Biology-driven classificaion of childhood acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group and Children’s Cancer Group Blood, 2004; 104:151a(Presented, ASH)2004
Angiolillo AL, Davenport V, Krailo M, Jakacki R, Pullen J, Bonilla MA, Reaman G, Cairo MS: Preliminary results of pre and post thrombopoietin prior to and after ICE chemotherapy iosfamide/carboplatin/ etoposide) in children with solid tumors: A Children’s Oncology Group report Proc Am S Clinical Oncol, 2003; 22:175(Presented, ASPHO)2003
Heerema NA, Shuster J, Biegel J, Camitta B, Cooley LD, Hirsch B, Magenis HE, Patil S, Pettenati MJ, Pullen J, Raimondi SC, Rao K, Schneider NR, Roulston D, Sanger W, Sather HN, Sutcliff MJ, van Tuinen P, Watson MS, Carroll AJ: Pattern of extra chromosomes in pediatric hyperdiploid (50 to 67 chromosomes) acute lymphoblastic leukemia (ALL) is modal number (mn) dependent Blood, 2002; 100:308a2002
DJ, Shuster JJ, Carroll AJ, Heerema NA, Camitta BM: Near triploidy, near tetraploidy in B-precursor ALL: the POG experience Presented by Dr. Camitta at the International Acute Lymphocytic Leukemia Rare Chromosome meeting,Vienna, Austria, April, 20022002
Savasan S, Stout M, Ozdimer O, Buck S, Pullen J, Ravindranath Y: The role of oxidative metabolism in In Vitro drug response in childhood AML and T-ALL Blood, 2001; 98:311a(Poster presentation, ASH)2001
Borowitz MJ, Shuster J, Viswanatha DS, Willman CS, Montgomery K, Pullen J, Carroll AJ, Camitta B: Correlation of end-induction minimal residual disease (MRD) in childhood acute lymphoblastic leukemia with clinical and biological risk factors. A Children's Oncology Group study Blood, 2001; 98:841a(Platform presentation, ASH)2001
Fernandes C, Leclerc GJ, Atlman-Hamandzic S, Shuster J, Pullen J, Camitta B, Safa AR, Barredo JC: Quantitative expression of multidrug resistance related protein (MRPI) and lung resistance protein (LRP) by real-time RT-PCR does not predict treatment outcome and survival in children with T-linage acute lymphoblastic leukemia Blood, 2001; 98:318a(Poster presentation, ASH)2001
Cox JA, Megason GC, Iyer RV, Loftis SF, Sullivan S, Smith MG, Mitchell T, Pullen DJ: Nasopharyngeal carcinoma in a patient with dominant dystrophic epidermolysis bullosa J Inves Med 49(1):106A, 20012001
Pullen J: Children's Oncology Group Designation for Low Risk Group in Childhood Acute Lymphocytic Leukemia American Society of Hematology Educational Workshop, December 3, 2000, San Francisco, CA2000
Shuster J, Link M, Camitta B, Pullen J, Behm F: Group sequential design of case-control studies for pediatric acute lyphoblastic leukemia cell bank International Society for Clinical Biostatistics, Trent, Italy, 9/4-8/20002000
Viswanatha DS, Bartolo C, Chen I-M, Camitta B, Pullen J, Willman C, Borowitz M: Comparisons of polymerase chain reaction and flow cytometry for the detection of minimal residual disease in pediatric acute lymphoblastic leukemia: A Pediatric Oncology Group study Blood, 2000 ;96:314a(Poster presentation, ASH)2000
Smith MG, Pullen DJ, Megason G, Mitchell T, Iyer RV: Streprococcus pneumoniae endophthalmitis in a patient with homozygous sickle cell disease Proceedings of 24th Annual Meeting of the National Sickle Cell Diseae Program, pg 187a, 2000 (poster presentation, Philadelphia PA, April 9-12, 2000)2000
Megason G, Weitman S, Blaney S, Winick N, Kuhn J, Pullen J, Bernstein M: A trial of 6-hyroxymethylacylfulvene (MGI-114) in children with solid tumors, a Pediatric Oncology Group phase I cooperative agreement study Proc Amer Soc Clin Oncol, 2000; 19:201a2000
Mitchell TE, Smith MG, Iyer RV, Pullen DJ: Xeroderma pigmentosum presenting as squamous cell carcinoma of the eyelid in a patient with sickle cell disease Proceedings of 24th Annual Meeting of the National Sickle Cell Disease Program, pg 165a, 2000 (poster presentation, Philadelphia PA, April 9-12, 2000)2000
Broome HE, Yu AL, Diccianni M, Pullen J, Monia BP Inhibition of BCL-xL expression sensitizes T-cell acute lymphocytic leukemia cells to chemotherapeutic drugs. Blood. 1999; 94:226b1999
Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Shuster JJ Allergy to E-coli L-asparaginase has no significant correlation with prognosis of childhood B-pecursor ALL: A Pediatric Oncology Group study. Med Pediatr Oncol. 1999;33:216 (Presented, SIOP/ASPHO)1999
Mitchell TE, Smith MJ, Iyer RV, Pullen DJ, Jones BP Xeroderma pigmentosum presenting as squamous cell carcinoma of the eyelid in a patient with sickle cell disease. J Invest Med. 1999;47:115a (poster presentation)1999
Rubnitz JE, Camitta BM, Raimondi SC, Carroll AJ, Borowitz MJ, Shuster JJ, Link MP, Pullen DJ, Downing JR, Behm FG, Mahmoud H, Pui C-H Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3): Favorable prognosis in T-cell cases. Blood. 1998;92:312a (presented, ASH)1998
Weir E, Carroll A, Pullen J, Head D, Camitta B, True mixed-lineage leukemia is a rare disease with poor outcome. A Pediatric Oncology Group study. Blood. 1998;92:398a (poster presentation, ASH)1998
Kaleem Z, Shuster JJ, Carroll AJ, Borowitz MJ, Pullen DJ, Camitta BM, Zutter MM,
Watson MS Acute lymphoblastic leukemia with t(8;14)(q11;q32): A Pediatric Oncology Group
study.
Blood. 1998;92:398a (poster presentation, ASH)
1998
Shah SJ, Taub JW, Radewan TL, Fu W, Moore D, Pollock BH, Zhang L, Amylon M, Behm FG,
Pullen J, Ravindranath Y, Matherly LH Relationship of p15 and p16 gene deletions to elevated dihydrofolate reductase in childhood acute lymphoblastic leukemia. Blood. 1998;92:220a (poster presentation, ASH)
1998
Li P, Shuster JJ, Pullen DJ, Borowitz MJ, Camitta BM, Carroll AJ RT-PCR detection of TEL/AML1 and AML1/TEL chimeric transcripts in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. ) Blood. 1998;92:392a (poster presentation, ASH1998
Wacker P, Shuster JJ, Pullen J, Humbert J, Land VJ, Mahoney DH, Lauer SJ, Look AT, Borowitz M, Carroll AJ, Camitta BM Interaction amonst gender, prognostic factors, and time in children with B-precursor acute lymphoblastic leukemia. Presented, International Society of Pediatric Oncology, 19981998
Whitehead VM, Payment C, Vuchich MJ, Cooley L, Lauer SJ, Mahoney DJ, Shuster JJ, Bernstein ML, Kamen BA, Look AT, Pullen DJ, Camitta B CR) The TEL-AML1 translocation and methotrexate polyglutamate levels in childhood B-progenitor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Proc Am Assoc Cancer Res. 1998;39:329 (poster presentation, AACR1998
Batova A, Diccianni MB, Yu J, Bridgeman L, Pullen J, Amylon MJ, Yu AL Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia. Proc Am Assoc Cancer Res. 1998;39:470 (poster presentation, AACR)1998
Omura-Minamisawa M, Diccianni MB, Batova A, Pullen J, Bowman WP, Yu AL Inactivation of p16 cell cycle regulatory pathway by specific targeting of p16 but not the downstream components in T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood. 1997;90:492a (presented, ASH)1997
Hunger SP, Fall MZ, Camitta BM, Carroll AJ, Link MP, Lauer SJ, Mahoney DH, Pullen DJ, Shuster JJ, Steuber CP, Cleary ML E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood. 1997;90:423a1997
Borowitz MJ, Rubnitz J, Nash M, Pullen DJ, Camitta B Predictability of the TEL-AML1 rearrangement from surface antigen phenotype in childhood B-precursor ALL. A Pediatric Oncology Group study. Blood. 1997;0:210b1997
Abish S, Carroll A, Shuster J, Camitta B, Pullen J A comparison of the balanced and unbalanced 1:19 translocation in childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood. 1997;90:185a (Poster presentation, ASH)1997
Maloney KW, Rubnitz JE, Cleary ML, Frankel L, Hakami N, Link MP, Pullen DJ, Hunger SP Lack of homozygous p16INK4A (p16) or p15INK4B (p115) gene deletion in infant acute lymphoblastic leukemia. Proc Am Soc Clin Onco. 1997; 16:515a (presented, ASCO)1997
Harris MB, Land VJ, Shuster JJ, Borowitz MJ, Behm FG, Pullen DJ Treatment of childhood acute lymphoblastic leukemia with consolidation of remission using anti-metabolite based therapy: A Pediatric Oncology Group study. Proc Am Soc Clin Oncol. 1997;16:515a (presented, ASCO)1997
Shuster JJ, Camitta BM, Pullen J, Borowitz MJ, Carroll AJ, Look AT, Mahoney DH, Lauer SJ, Land VF Identification of newly diagnosed children with acute lymphocytic leukemia at high risk for relapse. Proc Marrow Transplantation in Children, July 1996, Ft. Lauderdale FL (presented)1996
Yu AL, Batova A, Diccianni MB, Pullen J, Link MP, Yu J Preferential inactivation of p15 INK4B but not p16 INK4A by hypermethylation in T-cell acute lymphocytic leukemia. Blood. 1996;88(10):1408 (Presented, ASH)1996
Maloney KW, Rubnitz ME, Cleary ML, Frankel L, Hakami N, Link MP, Pullen DJ, Hunger SP Lack of ETV6 (TEL) Rearrangements in infant acute lymphoblastic leukemia. Blood. 1996;88(10):72a (presented, ASH)1996
Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM, Pui C-H, Downing JR,
Behm FG Case-control study of children with acute lymphoblastic leukemia confirms the favorable impact of TEL gene rearangements: A Pediatric Oncology Group study. Blood. 1996;88(10):450a (presented, ASH)
1996
Mahoney DH, Nitschke R, Shuster J, Winick N, Lauer S, Pullen, Steuber P, Camitta B Comparison of intensive methotrexate/mercaptopurine vs low-dose repetitive MTX/MP for lower risk acute lymphoblastic leukemia. A Pediatric Oncology Group randomized phase III study. Proc Am Soc Clin Onocl. 1996;15:336 (presented ASCO)1996
Harris MB, Land VJ, Shuster JJ, Borowitz MJ, Behm FG, Pullen DJ Consolidation therapy with intermediate dose methotrexate (IDM) alone, or IDM and L-asparaginase, or IDM and cytosine arabinoside in standard risk acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group study. Blood. 1996;88(10):668a (presented, ASH)1996
Behm FG, Carroll A, Shuster J, Camitta B, Link M, Lauer S, Land V, Steuber P, Crist W, Pullen DJ Rearrangement of the MLL gene identifies a subgroup of non-infant children with precursor-B ALL at high risk for treatment failures. A Pediatric Oncology Group study. Proc Am Assoc Cancer Res. 1996;37:186 (presented AACR)1996
Whitehead VM, Vuchich M-J, Carroll A, Lauer S, Mahoney D, Shuster J, Payment C, Bernstein M, Akabutu J, Bowen T, Kamen B, Ravindranath Y, Ememi A, Beardsley P, Pullen J, Camitta B Translocations involving chromosomes 12p, methotrexate metabolism and outcome in childhood B-progenitor cell acute lymphoblastic leukemia: A Pediatric Oncology Group pharmacology pilot study. Proc Am Assoc Cancer Res. 1996; 37:381 (presented AACR)1996
Alvarado CS, Austin GE, Borowitz M, Shuster J, Zaki S, Hakami N, Pullen J Myeloperoxidase (PO) gene expression in infant leukemia: A Pediatric Oncology Group study. Blood. 1995;86(10):330a (presented ASH)1995
Yu AL, Diccianni MB, Batova A, Vu T, Pullen J, Amylon M, Pollock B, Yu J High frequency alterations of the p16 and p15, but not p18, DCK inhibitors in T cell acute lymphoblastic leukemia. Blood. 1995;86(10):268a (presented ASH)1995
Borowitz MJ, Shuster J, Carroll AJ, Look AT, Camitta B, Mahoney D, Lauer S, Pullen DJ Prognostic significance of antigen fluorescence intensity (FI) in B-precursor acute lymphoblatic leukemia: Early outcome data from the Pediatric Oncology Group. Blood. 1995;86(10):41a (presented ASH)1995
Lauer SJ, Toledano S, Winick N, Munoz L, Mahoney D, Pullen J, Steuber CP, Shuster J, Camitta B A comparison of early intensive methotrexate/mercaptopurine vs early intensive alternating chemotherapy for high risk acute lymphoblastic leukemia. A Pediatric Oncology Group randomized phase III study. Proc Amer Soc Clinic Oncol. 1995;14:342 (presented, ASCO)1995
Camitta B, Land V, Lauer S, Mahoney D, Pullen J, Shuster J Risk adapted therapy for ALL: The Pediatric Oncology Group experience. Presented Acute Leukemias VI: Prognostic Factors and Treatment Strategies. Munster, Germany, 2/28/951995
Whitehead VM, Vuchich M-J, Carroll AJ, Lauer SJ, Mahoney D, Shuster JJ, Payment C,
Koch PA, Akabutu JJ, Bowen T, Kamen BA, Ravindranath Y, Emami A, Beardsley GP,
Pullen DJ, Camitta B Relation of methotrexate polyglutamate (MTXPG) accumulation in lymphoblasts to trisomy of both chromosomes 4 and 10 and to ploidy in childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood. 1994;84(10):515a (presented, ASH)
1994
Head DR, Borowitz M, Cerezo L, Craven C, Boyett J, Falletta J, Crist W, Pullen J, Humphrey B Reliability of punctate acid phosphatase positivity as a marker of T-cell acute lymphocytic leukemia in childhood. Blood 64(5):191a, 19841994
Mahmoud HH, Schwartz C, Shuster J, Pui CH, Behm F, Amylon M, Raimondi S, Borowitz M, Link M, Pullen J, Camitta B, Hakami N, Crist W, Carroll A The (11;19) translocation is associated with poor outcome in infants with acute lymphoblastic leukemia. A collaborative study of the POG and SJCRH. Med Ped Oncol. 1994, XXVIth Annual Meeting, International Society of Pediatric Oncology (SIOP), Paris, September 19941994
Megason G, Moulder S, Pullen D The use of in vitro culture assays to predict in vivo response to various therapeutic modalities in a patient with Diamond-¬Blackfan anemia. ) J Cell Biochem. 1994;18A:33 (Poster presentation, 1994 Keystone Symposia on Hematopoiesis1994
Lauer S, Shuster J, Kirchner P, Kiefer G, Pullen J, Camitta B, Land V Prognostic significance of cerebrospinal fluid lymphoblasts at diagnosis in children with acute lymphoblastic leukemia. ) Proc Amer Soc Clin Onco. 1994; 13:317 (Presented, ASCO1994
Pettenati MJ, Rao PN, Schnell S, Carroll AJ, Harris MJ, Pullen J, Martin PL Retrospective/ prospective investigation using FISH to detect chromosome 4 and 10 aneuploidy as a predictor of very good risk pediatric ALL. Am J Hum Genet. 1993;53:a342 (Poster presentation, American Society of Human Genetics)1993
Moulder S, Megason G, Pullen D The use of cell culture models to determine a possible course of treatment for a patient with Diamond-Blackfan anemia. Clin Res. 1993;40(4):730a (Poster presentation, Southern Society for Pediatric Research)1993
Megason GC, Hardy CL, DeBauche DM, Lewis RE, Pullen DJ Synergistic effects of hematopoietic cytokines on in vitro cultures from patients with acute myelogenous leukemia. Blood. 1992;82(10):651a1993
Herden MJ, DeBauche DM, Pullen DJ . Detection of the Mbcr-abl rearrangement by interphase-fluorescent in-situ hybridization in CML Blood. 1993;82(10):525a1993
Rubnitz JE, Link JP, Shuster JJ, Carroll AJ, Hakami N, Frankel L, Pullen DJ, Cleary ML Frequency and significance of HRX rearrangements in infant leukemia. Blood. 1993;82(10):190a (poster presentation, ASH)1993
Megason GC, Vedanarayanan V, Iyer RV, Belue A, Pullen J Coagulation abnormalities in patients with sickle cell disease and cerebrovascular accidents. Poster presentation, Eighteenth Annual Meeting of National Sickle Cell Disease Program, May, 19931993
Pui C-H, Raimondi SC, Borowitz MJ, Land VJ, Behm FG, Pullen DJ, Hancock ML, Shuster JJ, Steuber CP, Crist WM, Civin CI, Carroll AJ Acute lymphoblastic leukemia in children with Down syndrome. Proc Amer Soc Clin Onco. 1993; 12:3191993
Borowitz MJ, Carroll AJ, Hunger SP, Shuster JJ, Crist WM, Cleary ML, Pullen DJ The t(1;19) (E2A-PBX1) translocation in childhood ALL is associated with a specific immunophenotype. Modern Pathol. 1993;6:86a1993
Megason GC, Hatten BH, Kruckeberg WC, Pullen DJ The evaluation of secondary hyperphenylalaninemia by measuring the level of phenylalanine in the cerebrospinal fluid of children receiving methotrexate chemotherapy. Proceedings of the Greenwood Genetic Center. 1992;12:153 (Poster presentation, Southern Genetics Group, 7/10/921993
Megason GC, Smith J, Iyer RV, Pullen DJ, Carey T Aplastic crisis due to human parvovirus (B19) in two patients with glucose 6 phosphate dehydrogenase deficiency. Clinical Research. 1992;40(4):785a (Poster presentation, SSPR)1992
Iyer RV, Megason GC, Herden MJ, Smith MG, Pullen DJ Tri-lineage response to granulocyte macrophage colony stimulating factor in the treatment of severe refractory aplastic anemia. Blood. 1992;80(10)415a1992
Smith JC, Megason GC, Iyer RV, Pullen DJ Epidemiology of human parvovirus (B19) infections and aplastic crisis in patients with hereditary hemolytic anemias treated in tertiary care centers. Proc Southern Medical Assoc. 1992; abst P73 (presented, SMA)1992
Bowman WP, Shuster J, Cook B, Behm F, Pullen J, Berard C, Murphy S Improved survival for children with B cell (SIg+) acute lymphoblastic leukemia (B-ALL) and stage IV small non- cleaved cell lymphoma. Proc Amer Soc Clin Oncol. 1992;11:277 (presented, ASCO)1992
Quddus FF, Leventhal BG, Boyett JM, Pullen DJ, Borowitz MJ, Shuster JJ, Kato GJ Higher glucocorticoid receptor level is a favorable prognostic factor in childhood acute lymphocytic leukemia: A Pediatric Oncology Group study. Blood. 1991;78(10):391 (poster presentation, ASH)1991
Abshire TC, Buchanan GR, Jackson JF, Shuster JJ, Brock B, Head D, Behm FG, Crist WM, Link MP, Borowitz M, Pullen DJ Morphologic, immunophenotypic, and cytogenetic studies at time of first marrow relapse in children with acute lymphoblastic leukemia: Comparison with results at diagnosis and effect on outcome. Blood. 1991;78(10):171a (presented, ASH)1991
Bash RO, Crist WM, Link MP, Shuster JJ, Amylon M, Pullen J, Buchanan GR, Baer R: \ Clinical features and outcome in childhood T-cell acute lymphoblastic leukemia (T-ALL) with the tal rearrangement. Blood. 1991;78(10):325 (poster presentation, ASH)1991
Shuster J, Carroll A, Look T, Borowitz M, Crist W, Pullen J, Steuber P, Land V Trisomy of chromosome 4,10, or 18 and hyperdiploidy predict better outcome in B-progenitor pediatric acute lymphoblastic leukemia: A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol 10:234, 1991 (Presented, ASCO)1991
Shuster J, Look T, Crist W, Borowitz M, Carroll A, Pullen J, Steuber P, Land V Clinical features and tumor cell DNA index improve prediction of treatment outcome in pediatric B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol. 1991;10:234 (Presented, ASCO)1991
Borowitz MJ, Carroll AJ, Shuster JJ, Behm FG, Pullen DJ, Frankel L, Crist WM, Land V A unique immunophenotype defines cases of childhood acute lymphoblastic leukemia with chromosome 11q23 abnormalities and poor outcome. A Pediatric Oncology Group study. ) Modern Pathol. 1991;4:68a (Presented, US and Canadian Academy of Pathology1991
Borowitz MJ, Shuster JJ, Steuber P, Pullen DJ, Crist WM Intraclonal heterogeneity of cell surface antigen expression in chiodhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. Cytometry Supplement. 1991;5:43-44 (presented, XV Congress of the International Society for Analytical Cytology)1991
Whitehead VM, Vuchich M-J, Carroll AJ, Shuster JJ, Lauer S, Mahoney D, Akabutu J, Bowen T, Beardsley P, Leclerc J-M, Pullen DJ Methotrexate metabolism in lymphoblasts with hyperdiploidy and/or translocations in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood. 1990;76(10):335a1990
Pui C-H, Frankel LS, Carroll AJ, Raimondi SC, Shuster JJ, Head DR, Crist WM, Land VJ, Pullen DJ, Steuber CP, Behm FG, Borowitz MJ Childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23). Blood. 1990;76(10):310a (presented, ASH)1990
Abdel-Mageed A, Ragab AH, Shuster JJ, Pullen J, van Eys J, Sullivan MP, Boyett J, Borowitz M, Frankel LS, Crist WM Children with Down's syndrome and acute lymphocytic leukemia: Presenting features and outcome of therapy: A Pediatric Oncolgy Group study. Proc Amer Soc Clin Oncol. 1990;9:216 (presented, ASCO)1990
Land VJ, Shuster JJ, Carroll AJ, Borowitz MJ, Harris MB, Pullen DJ, Look AT A DNA index greater than 1.16 in B-precursor childhood acute lymphoblastic leukemia predicts a 95 percent 3-year event-free survival. Blood. 1990;76(10):292a (presented, ASH)1990
Pui C-H, Carroll AJ, Head D, Raimondi SC, Land VJ, Crist WM, Link MP, Behm FG, Nash M, Pullen DJ, Look AT Near-triploidy and near-tetraploidy in acute lymphoblastic leukemia of childhood. Proc Amer Soc Clin Oncol. 1990;9:216 (presented, ASCO)1990
Carroll AJ, Crist WM, Shuster J, Behm FG, Vietti TJ, Ragab A, Pullen DJ, Land VJ The poor prognosis of children with pre-B acute lymphoblastic leukemia is strongly associated with the t(1;19)(q23;p13). Blood. 1989;74(7):197a (presented, ASH)1989
Land VJ, Shuster JJ, Pullen J, Harris M, Krance RA, Castleberry R, Akabutu J, Barbosa JL, Rosen D Unexpectedly high incidence of allergic reactions with weekly high dose asparaginase early intensification therapy in children with newly diagnosed non-T, non-B acute lymphocytic leukemia. A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol. 1989;8:2151989
Pui C-H, Carroll AJ, Raimondi SC, Land VJ, Crist WM, Williams DL, Pullen DJ, Borowitz
MJ, Behm FG, Look AT Near-haploidy and hypodiploidy <45 in acute lymphoblastic leukemia of childhood. Blood. 1989;74(7):158a (presented, ASH)
1989
Borowitz M, Shuster J, Behm F, Look T, Carroll A, Land V, Pullen J, Crist W Prognostic significance of surface antigen phenotype in B-precursor ALL: A recursive partitioning analysis. Proc Amer Assn Ca Re. 1989; 30:230 (Presented, AACR)1989
Land VJ, Pullen DJ, Shuster JJ, Alvarado C, Amylon M, Harris MB Continuing improvement of outcome in childhood non-T, non-B acute lymphocytic leukemia: Pediatric Oncology Group experience in the 1980's. Blood. 1989;74(7):80a (poster presentation, ASH)1989
Russo C, Carroll A, Borowitz M, Kohler S, Shannon K, Forman E, Cook B, Amylon M,
Pullen J, Link M The Philadelphia chromosome with monosomy 7 in childhood acute lymphoblastic leukemia. Proc Amer Soc Clin Oncol. 1989;8:212(Presented, ASCO)
1989
Pullen J, Boyett J, Crist W, Johnson W, Iyer R, Frankel L, Gross S, Dubowy R, Berry D, Vietti T Intermediate dose methotrexate pulses during maintennce provide significantly improved protection for the testicular sanctuary in boys with non-T, non-B acute lymphocytic leukemia (ALL). A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol. 1989;8:211 (Presented, ASCO)1989
Borowitz MJ, Shuster JJ, Civin CI, Behm FG, Carroll A, Crist W, Pullen DJ CD34 expression is a favorable prognostic marker in B-precursor childhood acute lymphoblastic leukemia. Modern Pathol. 1989;2:11A (Presented, United States and Canadian Academy of Pathology)1989
Carroll AJ, Raimondi SC, Borowitz MJ, Amylon MD, Rivera G, Pullen DJ, Crist WM A new nonrandom 8;14 translocation in children with acute lymphoblastic leukemia. Am J Hum Genet. 1988;43:A211988
Crist W, Boyett J, Frankel L, Iyer R, van Eys J, Sullivan M, Harris M, Ravindranath Y, Pullen J Extended triple intrathecal chemotherapy (TIC) is highly effective and superior to brief TIC and intermediate-dose MTX (IDM) as CNS prophylaxis in non-T, non-B ALL. A Pediatric Oncology Group study. Presented August 1988, International Society of Paediatric Oncology SIOP XX meeting1988
Frankel LS, Shuster J, Dubowy R, Bowman P, Chauvenet A, Carroll AJ, Pullen J Seeking a better understanding of why infants with leukemia fail to maintain r¬mission. A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol. 1988;7:1931988
Link MP, Borowitz MJ, Behm FG, Jackson A, Brock B, Shuster JJ, Pullen J Rapid immunodiagnosis of childhood acute lymphoblastic leukemia using a screening kit. Proc Amer Soc Clin Onco. 1988; 7:1801988
Amylon M, Murphy S, Pullen J Treatment of lymphoid malignancies according to immune phenotype: Preliminary results in T-cell disease. Proc Amer Soc Clin Oncol. 1988;7:225 (Presented, ASCO)1988
Jackson JF, Boyett J, Pullen J, Brock B, Patterson R, Land V, Borowitz M, Crist W Improved prognosis in childhood acute lymphocytic leukemia (ALL) with hyper¬diploidy correlates with extra chromosome six. A Pediatric Oncology Group study. Proc Amer Soc Clin Onco. 1988; 7:178 (Presented, ASCO)1988
Borowitz MJ, Civin CI, Behm FG, Falletta JM, Shuster J, Carroll A, Look T, Pullen DJ, Crist WM Phenotypes encountered in B-lineage acute lymphoblastic leukemia (ALL) do not reflect stages of normal B-cell differentiation. A Pedia¬tric Oncology Group study. Lab Invest. 1988;58(1):11A (Presented, International Academy of Pathology)1988
Nuss R, Kirchingman G, Cross A, Zipf T, Antoun G, Bernstein I, Behm F, Pullen D, Crist W, Mirro J, Gorrha R T cell receptor gene rearrangements distinguish between infants and children with CALLA negative acute lymphoblastic leukemia. Blood. 1987;70(5):265a (presented, ASH)1987
Sullivan MP, Crist W, Pullen J, Jackson J, Head D, Borowitz M, Murphy S, Shuster J Childhood B-cell acute lymphocytic leukemia (ALL) is unexpectedly clinically heterogeneous: A Pediatric Oncology Group study. Proc Amer Soc Clin Onco. 1987; 6:148 (Presented, ASCO)1987
Carroll AJ, Link MP, Pullen DJ, Shuster JJ, Crist WM Cytogenetic features in children with T-cell acute lymphoblastic leukemia. Blood. 1987;70(5):276a (Presented, ASH)1987
Frankel LS, Ochs J, Shuster J, Dubowy R, Bowman P, Hockenberry M, Leventhal B, Carroll AJ, Pullen J Pilot protocol improves remission for infant leukemia and provides detailed laboratory characterization. Proc Amer Soc Clin Oncol. 1987;6:1611987
Pullen J, Boyett J, Borowitz M, Dowell B, Falletta J, Krejmas N, Sexauer C, Crist W How important is common acute lymphocytic leukemia antigen (CALL) negativity as a prognostic factor in children excluding infants with B-precursor acute lymphocytic leukemia (ALL)? A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol. 1987;6:151(Presented, ASCO)1987
Hurwitz C, Loken M, Graham M, Karp J, Borowitz M, Pullen J, Civin C Asynchro¬nous antigen epression in B-lineage acute lymphoblastic leukemia (ALL). Blood. 1987;70(5):260a1987
Boyett J, Pullen J, Jackson J, Vietti T, Borowitz M, Patterson R, Winick N, Crist W Pre-B phenotype of childhood acute lymphocytic leukemia (ALL) has prognostic importance independent of cytogenetic and other known risk factors. A Pediatric Oncology Group study. Blood. 1987; 70(5):198a (Presented, ASH).1987
Carroll AJ, Link MP, Ragab AH, Pullen DJ, Crist WM A nonrandom tramslocation, t(1;14), in children with T-cell acute lymphoblastic leukemia. Am J Hum Genet. 1987;41:A24 (Presented American Society of Human Genetics)1987
Carroll AJ, Raimondi SC, Pullen DJ, Crist WM tdic (9;12): A non-random chromosome abnormality in childhood B-cell acute lymphoblastic leukemia (ALL). Am J Hum Genet. 1986;39:A28 (presented, American Society of Human Genetics)1986
Carroll AJ, Frankel LS, Pullen DJ, Crist WM Acquired cytogenetic abnormalities in blast cells of infants with acute lymphoblastic leukemia. Blood. 1986;68(5):252a (Presented, ASH)1986
Downing J, Crist W, Pullen J, Vietti T, Grossi C, Prasthofer E, Burrows P T¬-cell antigen receptor B chain (Ti) and immunoglobulin (IG) gene rearrangements (REAR) in childhood T-cell acute lymphoblastic leukemia (T-ALL): Evidence for lineage infidelity. Lab Inves. 1986; 54(i):17a1986
Scroggs M, Boyett J, Falletta J, Pullen DJ, Jackson J, Russell E, Crist W, Borowitz M Clinicopathologic significance of immunophenotypic subgroups of B-¬lineage acute lymphocytic leukemia (ALL). A Pediatric Oncology Group (POG) study. Proc Amer Assoc Cancer. 1986 Res 27:201 (Presented, AACR)1986
Frankel LS, Pullen J, Boyett J, Eastment C, Ragab A, Hvizdala E, Berry D, Sexauer C, Crist W, Vietti T Excessive drug toxicity in children with Down's syndrome (DS) treated for acute lymphocytic leukemia (ALL) despite similarity of clinical and biological features to other patients. Proc Amer Soc Clin Oncol. 1986;5:1611986
Craven CM, Head DR, Pullen J, Ligorsky R Specific esterase (SE) staining in monoblastic (M5) leukemia. Blood 66(5):172a, 19851985
Russell E, Mohanakumar T, Boyett J, Pullen J, Crist W, Borowitz J, Falletta J, Leventhal B, Harris M, Maurer HM for the Pediatric Oncology Group Receptors for peanut agglutinin in childhood acute lymphoblastic leukemia: Clinical and biologic correlates. Blood 66(5):228a, 19851985
Pullen J, Jackson J, Crist W, Carroll A, Boyett J, Borowitz M, Brock B, Iyer R, Buchanan G, Head D, McWilliams N, Ragab A Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL) in children has clinical and biologic features that predict poor prognosis and is cytogenetically and immunopheno¬typically heterogeneous. Blood 66(5):181a, 1985 (Presented, ASH)1985
Falletta JM, Pullen DJ, Shuster JJ, Borowitz MJ for the Pediatric Oncology Group E-rosette positive (ER+), T antigen positive (T cell) acute lymphocytic leukemia (ALL) - Patterns of relapse. Pediatr Res 19(4):261A, 19851985
Adams JG, Morrison WT, Pullen DJ, Abney RL, Steinberg MJ Hemoglobin Mississippi (MS): A new hemoglobin variant with three distinct electrophoretic mobilities. Clin Res 33(2):603A, 19851985
Weiner M, Borowitz M, Boyett J, Civin K, Metzgar R, McKolnis J, Crist W, Dowell B,
Pullen J for the Pediatric Oncology Group ) Clinical pathologic aspects of myeloid antigen positivity in pediatric patients with acute lymphoblastic leukemia (ALL). Proc Amer Soc Clin Oncol 4:172, 1985 (Presented, ASCO
1985
Pullen J, Crist W, Boyett J, Falletta J, van Eys J, Borowitz M, Jackson J, Dowell B, Frankel L, Quddus F, Ragab A, Vietti T Infants have biologically different and clinically more aggressive acute lymphocytic leukemia (ALL) than older children. Proc Amer Clin Oncol 4:163, 1985 (Presented, ASCO)1985
Boyett JM, Pullen DJ, Sullivan MP, Falletta JM, Humphrey GB, Starling KA, Land VJ, Vats TS, Ragab AH, Crist WM for the Pediatric Oncology Group Modified LSA2¬L2 treatment in 53 children with E-rosette-positive T-cell leukemia (T-ALL): Cures and factors predictive of CNS relapse. Proc Amer Soc Clin Oncol 4:163, 19851985
van Eys J, Berry D, Crist W, Doering E, Fernbach D, Pullen J, Shuster J for the Pediatric Oncology Group Effect of Trimethoprim/Sulfamethoxazole (TS) prophylaxis on outcome of childhood acute lymphocytic leukemia (ALL). Proc Amer Soc Clin Oncol 4:154, 1985 (Presented, ASCO)1985
van Eys J, Pullen J, Head D, Boyett J, Crist W, Falletta J, Humphrey GB, Jackson J, Riccardi V, Brock B The French American British (FAB) classification: The Pediatric Oncology Group (POG) experience with acute lymphocytic leukemia (ALL). Blood 62(5):185a, 1983 (Poster presentation, ASH)1984
Grossi C, Crist W, Prasthofer E, Civin C, Griffith R, Harris D, Humphrey B, Freeman A, Pullen J Maturational staging of childhood T-cell malignancies: Cytochemical and ultrastructural studies complement immunologic analysis. Blood 64(5):147a, 1984 (Presented, ASH)1984
Crist W, Pullen J, Boyett J, Falletta J, van Eys J, Borowitz M, Jackson J, Dowell B, Quddus F, Ragab A, Vietti T Clinical and biologic features predict poor prognosis in acute lymphocytic leukmia (ALL) in infants. Presented at the International Society of Pediatric Oncology Meeting, Barcelona, Spain. SIOP Abstracts page 198, September 19841984
Quddus FF, Kaufmann SH, Boyett J, Pullen J, Borowitz M, Crist W, Leventhal BG: Correlation of lymphoblast glucocorticoid receptor (GR) number and patient characteristics in childhood acute lymphocytic leukemia (ALL). Proc Amer Assoc Cancer Res 25:206, 1984 (Poster presentation, AACR)1984
Borowitz MJ, Boyett JM, Dowell BL, Pullen DJ, Metzgar RS, Humphrey GB, van Eys J, Falletta JM Clinicopathologic aspects of E rosette negative T cell acute lymphoblastic leukemia (T-ALL). Proc Amer Soc Clin Oncol 3:18, 19841984
Dowell BL, Boyett JM, Borowitz MJ, Falletta JM, Pullen DJ, Crist WM, van Eys J, Metzgar RS, Starling KA, Humphrey GB Immunologic and clinicopathologic features of common acute lymphocytic leukemia antigen (CALLA)-positive, T cell leukemia. Proc Amer Soc Clin Res 25:783, 1984 (Presented, ASCO)1984
Pullen J, Crist W, Boyett J, Falletta J, van Eys J, Borowitz M, Jackson J, Dowell B, Russell C, Quddus F, Ragab A, Vietti T Clinical and biologic features predict poor prognosis in adolescent acute lymphocytic leukemia (ALL). Proc Amer Soc Clin Oncol 3:199, 1984 (Presented, ASCO)1984
van Eys J, Shuster J, Pullen J, Berry D, Crist W, Doering E, Fernbach D, Moore T Intensity of therapy and infections in pediatric leukemia. Proc Amer Soc Clin Oncol 2:80, 1984 (Presented ASCO)1984
Barger B, Dearth J, Crist W, Humphrey B, Ragab A, Pullen J, Go R, Vietti T, Acton R HLA associations in black and white children with non-T, non-B acute lymphocytic leukemia. Blood 62(5):165a, 19831984
Sullivan MP, Pullen J, Chen T, Moore T, Doering EJ, Falletta JM, Trueworthy R SWOG trial of LSA2-L2 therapy. International Society of Pediatric Oncologists. Budapest, Hungary, 9/23/83 (Presented, SIOP)1983
Falletta J, Boyett J, Pullen J, Crist W, Humphrey GB, Metzgar R Black children have common acute lymphocytic leukemia (ALL) less often than do white children. Proc Amer Assoc Cancer Res 2:127, 19831983
Humphrey GB, Pincus JK, Pullen DJ, Falletta JM, Metzgar RS, van Eys J, Boyett JM, Shuster JJ AACR) An analysis of two definitions of T-cell leukemia (TCL) by the Pediatric Oncology Group (POG). Proc Amer Assoc Cancer Res 2:127, 1983 (Presented, AACR)1983
Boyett J, Pullen J, Crist W, van Eys J, Berry D, Leventhal B, Kim T, Ravindranath Y, Dowell B, Roper M Immune phenotype is an independent prognostic factor within non-T, non-B acute lymphocytic leukemia (ALL): Initial WBC is not prognostic within pre-B ALL. Blood 60(5):121a, 1982 (Presented, ASH)1982
Crist W, Roper M, Jackson J, Pullen J, Humphrey B, Boyett J, Metzgar R, van Eys J, Falletta J, Cooper M Childhood pre-B cell leukemia responds less well to therapy. Presented International Society of Pediatric Oncology XIVth Meeting, Bern, Switzerland. SIOP Abstracts page 13. 9/21-25/821982
Roper M, Crist W, Metzgar R, Ragab A, Smith S, Starling K, Pullen J, Leventhal B, Bartolucci A, Cooper M Monoclonal antibody characterization of surface antigens in childhood T-cell malignancies. Presented International Society of Pediatric Oncology XIVth Meeting, Bern Switzerland. SIOP Abstracts page 59. 9/21-25/821982
Quddus FF, Kaufmann SH, Roper M, Dowell B, Pullen J, Leventhal BG Glucocorticoid receptor (GR) level in pediatric leukemia cells. Proc Amer Clin Oncol 1:131, 19821982
Falletta JM, Pincus JK, Metzgar RS, Pullen DJ, Humphrey GB, Crist WM, Boyett J, van Eys J: Reduced efficacy of vincristine-prednisone in some patients with T¬cell leukemia. Clin Res 29:893A, 1981 (Presented, SSPR)1981
Roper M, Crist W, Ragab A, Pullen J, Humphrey B, Boyett J, Metzgar R, van Eys J, Nix W, Cooper M: Pre-B cell leukemia differs in its response to therapy. Blood 59(5):150a, 1981 (Presented, ASH)1981
Humphrey GB, Blackstock R, Falletta JM, Metzgar R, van Eys J, Richie ER, Crist WM, Cooper MD, Pullen DJ, Shuster J, Boyett J, Maurer H, Whitehead VM: Expression of Fc and/or C' receptors on "ontologically immature and mature phenotypes" in acute lymphoblastic leukemia (ALL). Exper Hematol 9(9):79, 1981 (Presented, ISEH)1981
Sullivan MP, Pullen J, Moore T, Doering EJ, Falletta JM, Trueworthy R, Chen T: Pediatric Oncology Group trial of LSA2-L2 therapy in non-Hodgkin's lymphoma (NHL). Proc Amer Soc Clin Oncol 22:378, 1981 (Presented, ASCO)1981
Pincus JK, Falletta JM, Metzgar R, Pullen J, Crist W, Humphrey GB, Boyett J: The accuracy of identifying T cell leukemia using E rosetting of bone marrow lymphoblasts. Pediatr Res 15(4):602, 19811981
Pincus JK, Falletta JM, Metzgar R, Pullen J, Crist W, Humphrey GB, Boyett J, van Eys J: Thymocyte antigen in T cell leukemia. Pediatr Res 15(4):584, 19811981
Roper M, Crist W, Metzgar R, Nix W, Smith S, Pullen J, Ragab A, Cooper MD Immune phenotypes in childhood T-cell lymphoid malignancies. Proc Amer Soc Clin Oncol 22:374, 1981 (Presented, ASCO)1981
van Eys J, Chen TT, Berry D, Moore T, Crist W, Doering E, Fernbach D, Pullen J The effect of drug dosage on outcome and infectious complications in the treatment of childhood lymphocytic leukemia. Proc Amer Soc Clin Oncol 22:478, 19811981
Pincus JK, Falletta JM, Metzgar R, Pullen J, Crist W, Humphrey GB, McKnight MA, van Eys J The accuracy of identifying T cell leukemia using E-rosetting of bone marrow lymphoblasts. Clin Res 28(5):869a, 1980 (Presented, SSPR)1980
Frankel LS, Wang YM, Pullen J, Nitschke R, Doering EJ High dose intravenous (IV) methotrexate (MTX) with intrathecal (IT) MTX boost in the maintenance of acute lymphocytic leukemia (ALL) in children. Proc Amer Soc Clin Oncol 21:389, 19801980
Pullen J, Crist W, Falletta J, Humphrey G, Metzgar R, van Eys J, Vogler L Immunologic profiles in childhood acute lymphocytic leukemia (ALL). Proc Amer Assoc Cancer Res 21:247, 1980 (Poster presentation, AACR)1980
Humphrey GB, Crist W, Falletta J, Richie E, Ragab A, Pullen J The implication of thermostable and thermolabile T-cell leukemia in randomized trials (potential for prognostic significance). Proc Amer Assoc Cancer Res 20:289, 19791979
McKnight MA, Falletta JM, Metzgar R, Pullen J, Crist W, Humphrey GB, van Eys J Clinical and laboratory characteristics of T-antigen positive acute lymphocytic leukemia in children. Clin Res 27:816a, 1979 (Presented, SSPR)1979
Crist W, Vogler L, Sarrif A, Pullen J, Bartolucci A, Falletta J, Humphrey B,van Eys J, Cooper M Clinical and laboratory characterization of pre-B cell leukemia in children. Blood 54(5):183a, 19791979
Humphrey GB, Richie E, Falletta JM, Crist WM, Ragab AH, Pullen J The spectrumof the E receptor on bone marrow blasts in acute lymphoblastic leukemia (ALL) of childhood. Blood 54(5):189a, 19791979
Humphrey GB, Herson J, Pullen J, Crist W, Ragab A, Falletta J The role of thermal stability in the identification of two subsets of T-cell acute lymphoblastic leukemia. Inter Soc Experi Hematol 3:85, 1978 (Presented, ISEH)1978
Starling KA, Pullen J, Humphrey GB, Crist WM, Vats T, Sabio H Adriamycin, vincristine and prednisone for remission induction in acute myelogenous leukemia. Pediatric Res 11:481, 19771977
Lusher JM, Barnhart MI, Pullen J, Warrier AI Platelet function, ultrastructure, and management in Glanzmann's thrombasthenia. Thrombosis and Haemostasis 38:263, 19771977
Starling KA, Humphrey GB, Pullen J, Vats TS, Dyment P Vincristine and prednisone vs vincristine, prednisone and L-asparaginase for second remission induction in acute leukemia in children. Blood 46:289, 19751975
Lane DM, George SL, Komp D, Lonsdale D, Pullen J, Ragab A, Starling KA Continuous maintenance therapy following either continuous or discontinuous maintenance therapy in childhood leukemia. Proc Amer Soc Clin Oncol 15:166, 19741974
Berry D, Pullen J, Vietti T, Sullivan M, Fernbach D Comparison of prednisolone,vincristine, methotrexate and 6-mercaptopurine (POMP) vs vincristine and prednisone (V-P) induction in childhood acute leukemia. Proc Amer Assoc Cancer Res 15:33, 19741974
Pullen DJ: Platelet function in salicylate intoxication. Proc Southern Soc Pediatr Res, November 1968 (Presented, SSPR)1969
Pullen J, Boyett J, Frankel L, Iyer R, van Eys J, Crist W, Harris M, Ravindranath Y,
Sullivan MP Extended triple intrathecal (T.I.T.) chemotherapy provides effective central nervous system (CNS) prophylaxis for both good and poor prognosis patients with non-T, non-B acute lymphocytic leukemia (ALL): Substitution of in¬termediate dose methotrexate (IDM) for T.I.T. after consolidation provides less effective protection for the CNS. Proc Amer Soc Clin Oncol. 1988;7:176(Presented, ASCO)
1888
Land VJ, Shuster JJ, Pullen J, Harris M, Krance RA, Castleberry R, Akabutu J, Barbosa JL, Rosen D Unexpectedly high incidence of allergic reactions with weekly high dose asparaginase early intensification therapy in children with newly diagnosed non-T, non-B acute lymphocytic leukemia. A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol. 1989;8:215

Thesis

Pullen DJ Studies in platelet function. Thesis accepted June, 1969 by the Committee on Graduate Studies in Clinical Depts of the Univ of Tenn in partial fulfillment of requirements for the Degree of Master of Science in Pediatrics1969

Book Chapter

Pullen J: Acute leukemia in children In Rakel, Bope, editors, Conn's Current Therapy. WB Saunders Company, pp 449-454, 20012001
Borowitz MJ, Carroll AJ, Shuster JJ, Look AT, Behm FG, Pullen DJ, Land VJ, Crist WM Use of clinical and laboratory features to define prognostic subgroups in B¬precursor ALL. Experience of the Pediatric Oncology Group. Presented at the International Workshop on Recent Advances in Tumor Cell Biology in Acute Leukemias. Berlin, June 28-29, 1991. Recent Results in Cancer Research. 1993;131:257-269. Springer Publishers, Heidelberg, Germany1993
Crist WM, Pullen DJ, Rivera GH Acute lymphocytic leukemias. Chapter in Clinical Pediatric Oncology, 4th Edition, Vietti TJ, Fernbach DJ eds. The CV Mosby Co., St. Louis, Toronto, 305-335, 19911991
Pullen DJ, Boyett JM, Crist WM, Falletta JM, Roper M, Dowell B, van Eys J, Jackson JF, Humphrey GB, Metzgar RS, Cooper MD Pediatric Oncology Group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: Influence on treatment response. In Annals of the New York Academy of Sciences vol 428, pp 26-48, 1984. (Presented New York Academy of Sciences "Conference on Technology Impact: Potential Directions for Laboratory Medicine", 9/21/83). Selected for inclusion in Year Book of Cancer, 1986, RC Hickey, GF Saunders, RL Clark and RW Cumley (eds), Year Book Medical Publishers, Inc, Chicago, pp 183-1841984
Pullen DJ, Crist WM, Falletta JM, Boyett JM, Roper M, Dowell B, van Eys J, Humphrey GB, Head D, Brock BL, Blackstock R, Metzgar RS, Cooper MD A Pediatric Oncology Group classification protocol for acute lymphocytic leukemia (ALinC 13). Immunologic phenotypes and correlation with treatment results. In S Murphy and J Gilbert (eds), Leukemia Research: Advances in Cell Biology and Treatment. Elsevier, North Holland, Excerpta Medica Publishers, New York, pp 221-239, 1983. (Presented St. Jude Children's Research Hospital International Symposium on Leukemia Cell Biology and Therapy, 5/21/82, Memphis, TN.)1983
Pullen J Drug-induced thrombocytopenias. In Lusher JM, Barnhart MI (eds): Acquired Bleeding Disorders in Children, Abnormalities of Hemostasis, vol 3, New York, Masson, 1981, pp 49-631981

Letter to the Editor

Frankel LS, Wang YM, Shuster J, Nitschke R, Doering EJ, Pullen J ) The effect of early leukovorin rescue. J Clin Onco. 1984; 2(9):10721984

Electronic Publications

Pullen J (editor), Gidvani-Diaz V (editor), Aygun B, Carpenter S, Harper J, Herrington B, Hogan MJ, Kesselheim J, Rogers Z, Vik TA American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology Published monthly online January through December 20162016
Pullen J (editor), Gidvani-Diaz V (editor), Aygun B Carpenter S, Harper J, Herrington B, Hogan MJ, Kesselheim J, Rogers Z, Vik TA American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology Published monthly January through December 20152015
Pullen J (editor), Gidvani-Diaz V (editor), Aygun B, Carpenter S, Harper J, Herrington B, Hogan MJ, Kesselheim J, Rogers Z, Vik TA American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology Published monthly January through December 20142014
Arceci RJ (editor), Pullen J (editor), Gidvani-Diaz V, Hogan MJ, Kanwar VS, Kim J, Leavey PJ, Levy AS, Robers Z, Stoffman JM, Vik TA American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology Published monthly January through December 20132013
Arceci RJ (editor), Pullen J (editor), Gidvani-Diaz V, Hogan MJ, Kanwar VS, Kim J, Leavey PJ, Levy AS, Rogers Z, Stoffman JM, Vik TA American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology. Published monthly online January through December 20122012
Arceci RJ (editor), Pullen J (editor), Gidvani-Diaz V, Hogan MJ, Kanwar VS, Kim J, Leavey PJ, Levy AS, Rodriguez-Cortez H, Rogers Z, Stoffman JM, Vik TA American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology. Published monthly online January through December 2011 American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology, 20112011

Presentations

National Meeting of Children's Miracle Network Sponsors/Participating Institutions Staff, Acceptance of CMN Caregiver Award, Children's Miracle Network, Orlando FL03/2008
State/Local Invited Seminars/Lectures, Low Risk Acute Lymphocytic Leukemia in Children: Background and Current Status, MS Chapter, American Academy of Pediatrics Pediatric Hematology/Oncology Festschrift, Jackson, MS02/2006
National and International Invited Seminars/Lectures, Children's Oncology Group Designation for Low Risk Group in Childhood Acute Lymphocytic Leukemia, American Society of Hematology Educational Workshop, San Francisco, CA12/2000
National and International Invited Seminars/Lectures, Near Triploid, Near Tetraploid B-Precursor Acute Lymphocytic Leukemia, International Acute Lymphocytic Leukemia Workshop, Sausalito, CA12/2000
National and International Invited Seminars/Lectures, Pediatric Oncology Group Hypodiploidy in B-Precursor ALL, Montevideo Intergroup Rare Chromosome Initiative in Childhood Acute Lymphocytic Leukemia, Ponte di Legno, Italy05/1999

Honors, Awards, and Recognition

Lifetime Achievement Award for Class of 1961, Tulane University School of Medicine2011
The University of MS Medical Center, in December 2010, established an endowed chair for the Division of Pediatric Hematology/Oncology (named the D. Jeanette Pullen Chair). Dr. Gail Megason, current director of the division, is the initial recipient of this chair2010
Recipient, Resolution "Commending the service of Dr. Jeanette Pullen for her work at the University of Mississippi Medical Center's Children's Cancer Clinic, upon receiving the Childre's Miracle Network Achievement Award", State of Mississippi Legislature, House of Representatives, MS House of Representatives2008
Recipient, National Library of Medicine/UMC Rowland Medical Library Women Physicians Local Legends Award2008
Recipient, Women's Fund of the Community Foundation of Greater Jackson Community Service Award2008
Recipient, Children's Miracle Network Caregiver Award, Children's Miracle Network2008
Pediatric Hematology/Oncology Festschrift, MS Chapter, American Academy of Pediatrics2006
Charter Member, UMMC Chapter of National Gold Humanism Society2005
Listing, Best Doctors in America2005
Co-Chair, COG ALL Biology Committee2000
Co-Chair, COG ALL Risk Group/Classification Subcommittee1998
Vice Chair, POG New ALL Committee1994
Blair E. Batson Meritorious Service Award, MS Chapter, Americal Academy of Pediatrics1991
Chair, POG New ALL Classification and Reference Laboratory Directors' Committee1981
Chair, POG New ALL Committee1981
Principal Investigator, POG/COG for UMMC1970
Alpha Omega Alpha, Tulane University School of Medicine1961
Study Coordinator, POG 7615, Modified LSA2-L2 Therapy, T-cell leukemia portion
Study Coordinator, POG 7865, Pilot Acute Lymphocytic Leukemia of Childhood (ALinC) 13-Classification Protocol
Study Coordinator, POG 7866, Pilot ALinC 13-Treatment Protocol
Study Coordinator, POG 8035/8036, Laboratory Subclassification and Evaluation of Treatment Reginebs in Acute Lymphoid Leukemia of Childhood, ALinC 13C+T Protocols
Study Coordinator, POG 8305, SIMAL 3 and 4 Laboratory Reclassification Protocol
Study Coordinator, POG 8600, ALinC 14 Classification Protocol
Study Coordinator, POG 9000, ALinC 15 Classification Protocol
Study Coordinator, POG 9400, ALinC 16 Classification Protocol
Study Coordinator, POG 9900, ALinC 17 Classification Protocol
Study Co-coordinator, POG 9201/9605/9406 ALinC 16 Treatment Protocols
Study Co-coordinator, POG 9705 and 9806 ALinC 17 treatment Pilot Protocols
Study Co-coordinator, POG 9904, 9905, 9906 ALinC 17 Treatment Protocols
Study Co-cordinator, POG 9907, ALinC 17 Classification Cytogenetics Protocol
Recipient, State of Mississippi Legislature's Higher Education Appreciation Day, Working for Academic Excellence (HEADWAE) Award - UMC Outstanding Faculty Member1889

Professional Membership and Service

American Academy of Pediatrics, Co-Editor (PREP Hematology/Oncology) and Board Member, PREP Hematology-Oncology Self-Assessment Online Series2009 - Present
(Charter) UMMC Chapter of Gold Humanism Society, Member2005 - Present
Subboard of Pediatric Hematology/Oncology of the American Board of Pediatrics, Member2000 - 2005
Data Safety Monitoring Committee, St. Jude Children's Research Hospital (Chair 1999-2002), Member1999 - 2007
American Society of Pediatric Hematology/Oncology, Member1991 - Present
American Association of Cancer Research, Member1983 - Present
American Society of Clinical Oncology, Member1981 - Present
American Association of Cancer Education, Member1974 - Present
American Society of Hematology, Member1972 - Present
Pediatric Oncology Group/Children's Oncology Group, Member1970 - Present
Fellow, American Academy of Pediatrics, Member1967 - Present
Mississippi Chapter, American Academy of Pediatrics, Member
Mississippi State Medical Association, Member

Committee Service

Task Forces for UMC Cancer Center Planning, Chair2002 - 2003
Task Forces for UMC Cancer Center Planning, Chair2002 - 2003
UMC Institutional Cancer Research Committee, American Cancer Society, Member1996 - 2006
UMC Institutional Cancer Research Committee, American Cancer Society, Member1996 - 2006
UMC Department of Pediatrics Research Committee, Member1989 - 2006
UMC Department of Pediatrics Research Committee, Member1989 - 2006
UMC Transfusion Committee, Member1988 - 1994
MEDICAL CENTER-INSTITUTIONAL REVIEW BOARD 2, Member1975 - Present
UMC Clinical Cancer Activities Committee, Member1974 - 2005
UMC School of Medicine Cancer Research Advisory Committee, Member1971 - 1980
University of MS School of Medical Cancer Research Advisory Committee, Member1971 - 2008

Other Service

UMMC Scholarship Oversight Committees (two) for Pediatric Hematology/Oncology Fellows, Member07/2011 - 06/2014
UMMC Scholarship Oversight Committees (two) for Pediatric Hematology/Oncology Fellows, Chair07/2006 - 06/2010
Honorary Attending Physician, University of Mississippi Medical Center2006 - Present
UMMC Children's Cancer Fund Board of Directors, Member2006 - Present
Chief of Staff, University Hospital, Chief of Staff1985 - 12/1986
UMMC Children's Cancer Fund Board of Directors, Medical Advisor1979 - 2005
Attending Physician, University of Mississippi Medical Center07/1969 - 12/2005

Teaching Experience

Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsFall 2017
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsWinter 2017
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSummer 2017
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSpring 2017
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsFall 2016
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsWinter 2016
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSummer 2016
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSpring 2016
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsWinter 2015
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSpring 2015
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsFall 2014
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSummer 2014
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSpring 2014
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsWinter 2014
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsFall 2013
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSpring 2013
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSummer 2013
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsWinter 2013
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsFall 2012
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSummer 2012
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSpring 2012
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsWinter 2012
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsFall 2011
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSummer 2011
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSpring 2011
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsWinter 2011
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsFall 2010
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSummer 2010
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSpring 2010
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsWinter 2010
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsFall 2009
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSummer 2009
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSpring 2009
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsWinter 2009
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsFall 2008
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSummer 2008
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSpring 2008
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsWinter 2008
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsFall 2007
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSummer 2007
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSpring 2007
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsWinter 2007
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsFall 2006
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSummer 2006
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for FellowsSpring 2006
Medicine, Small Group, Course Director, Pediatric HematologyOncology Instruction for FellowsWinter 2006

Fellows supervised

Pediatric Hematology/Oncology Fellowship Training, Training Faculty, 9 fellows supervised, Weekly Teaching Sessions with Weekly Exams; Microscopy Teaching Sessions.01/2006 - Present